ПЕПТИДЫ, ИНГИБИРУЮЩИЕ АЦЕТИЛХОЛИНОВЫЕ РЕЦЕПТОРЫ, И ИХ ПРИМЕНЕНИЕ

Изобретение относится к ингибирующим ацетилхолиновые рецепторы пептидам и их применениям, при этом фаги с высокой аффинностью связывания в отношении ацетилхолиновых рецепторов подвергали скринингу с использованием произвольных пептидных рекомбинантных фагов и связывающие ацетилхолиновые рецепторы пептиды отбирали с помощью фаговой ДНК. Поскольку с использованием отобранных пептидов подтверждены аффинность связывания с ацетилхолиновыми рецепторами и эффект ингибирования действия ацетилхолиновых рецепторов, и подтверждены посредством модификаций пептидов, пептидных сайтов и последовательностей, которые имеют жизненно важное значение для связывания с ацетилхолиновыми рецепторами, предполагается, что ингибирующие ацетилхолиновые рецепторы пептиды в соответствии с настоящим изобретением будут использоваться при разработке косметической композиции для разглаживания морщин, лекарственного препарата для предупреждения или лечения ассоциированных с ацетилхолиновым рецептором заболеваний и оздоровительного ...

ПЕПТИДЫ, ВЫДЕЛЕННЫЕ ИЗ ЧЕЛОВЕЧЕСКОГО ЛАКТОФЕРРИНА, И ИХ ПРИМЕНЕНИЕ

Изобретение относится к новым пептидам, сконструированным на основании аминокислотной последовательности, соответствующей последовательности зрелого человеческого лактоферрина с 13 по 30 аминокислотный остаток, обладающим улучшенной противомикробной и/или противовоспалительной активностью, и их применению, в частности для лечения и/или предотвращения инфекций, воспалений, ран или рубцов. 6 н. и 3 з.п. ф-лы, 5 ил., 8 табл., 5 пр.

ПОЛИПЕПТИДЫ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ

Настоящее изобретение относится к области биотехнологии, в частности к новым пептидам для лечения рака. Изобретение раскрывает пептид, эффективный в блокировании CXC-хемокинового рецептора 4 (CXCR4). Изобретение может быть использовано в медицинской практике для контроля пролиферации раковых клеток при лечении злокачественных новообразований и ассоциированных с ними заболеваний. 3 н. и 6 з.п. ф-лы, 2 табл., 1 пр.

ЦИКЛОПЕПТИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ИЛИ АКТИВАТОРОВ АНТИОГЕНЕЗА

Изобретение относится к получению новых циклопептидов общей формулы цикло(R1 -Arg-Ile-Lys-Pro-His-R2), выбранных из следующих соединений: P11: цикло(DPhe-Pro-Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly-Glu) (SEQ ID NO: 5), P16: цикло (Arg-Ile-Lys-Pro-His-Gln-Gly) (SEQ ID NO: 8), P17: цикло(Pro-Arg-Ile-Lys-Pro-His-Gln-Gly) (SEQ ID NO: 9), P19: цикло(Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly-Glu) (SEQ ID NO: 10), P20: цикло(DPhe-Pro-Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly) (SEQ ID NO: 11), Р23: цикло (DPhe-Pro-Arg-Ile-Lys-Pro-His-Gln) (SEQ ID NO: 13), P24: цикло (Gly-Arg-Ile-Lys-Pro-His) (SEQ ID NO: 25), a также соединений P11, P20 и Р23, у которых DPhe заменен на DTyr. Циклопептиды применяют в системах для ингибирования ангиогенеза, включающих подложку, к которой присоединены циклопептиды посредством органической ножки, которая может содержать группировку, подверженную расщеплению какой-либо ферментативной системой. 8 н. и 15 з.п. ф-лы, 4 ил., 3 ...

ПОЛИПЕПТИДЫ АПРОТИНИНА ДЛЯ ТРАНСПОРТА СОЕДИНЕНИЯ ЧЕРЕЗ ГЕМАТОЭНЦЕФАЛИЧЕСКИЙ БАРЬЕР

Настоящее изобретение относится к области биотехнологии, конкретно к области доставки противоопухолевых средств в клетки млекопитающих. Изобретение позволяет получить конъюгат происходящего из апротинина полипептида Angiopep-2 с тремя молекулами таксола, который может быть использован в терапии пациентов, страдающих раком мозга. Полученный конъюгат способен эффективно преодолевать гематоэнцефалический барьер млекопитающего и доставлять лекарственное средство к клеткам мозга. 2 н. и 1 з.п. ф-лы, 9 ил., 6 табл., 3 пр.

КОНЪЮГИРОВАННАЯ ВАКЦИНА НА ОСНОВЕ ПЕПТИДА АНТИГЕНА WT1

Изобретение относится к соединению формулы (1), где Хи Yкаждый представляет собой одинарную связь, пептид А ракового антигена представляет собой пептид, состоящий из аминокислотной последовательности RMFPNAPYL (SEQ ID NO: 2), аминогруппа N-концевой аминокислоты пептида А ракового антигена присоединена к Yв формуле (1) и карбонильная группа С-концевой аминокислоты пептида А ракового антигена присоединена к гидроксильной группе в формуле (1), Rпредставляет собой пептид С ракового антигена, пептид С ракового антигена имеет последовательность, отличную от таковой пептида А ракового антигена, который является пептидом, состоящим из любой аминокислотной последовательности, выбранной из приведенных ниже аминокислотных последовательностей: CMTWNQMNL (SEQ ID NO: 3) и CYTWNQMNL (SEQ ID NO: 4), и тиоэфирная группа цистеинового остатка пептида С ракового антигена присоединена к тиоэфирной группе в формуле (1), или его фармацевтически приемлемой соли. Соединения формулы (1) могут найти применение для ...

НОВЫЙ ПРОНИКАЮЩИЙ В КЛЕТКИ ПЕПТИД, ЕГО КОНЪЮГАТ С БОТУЛОТОКСИНОМ И ИХ ПРИМЕНЕНИЕ

Изобретение относится к области биотехнологии и биохимии, в частности к проникающему в клетки пептиду. Указанный пептид состоит из аминокислотной последовательности SEQ ID NO: 1 и обладает способностью опосредовать внутриклеточную доставку легкой цепи ботулотоксина. Изобретение также относится к конъюгату для внутриклеточной доставки легкой цепи ботулотоксина. В указанном конъюгате легкая цепь ботулотоксина конъюгирована одним или обоими концами с аминокислотной последовательностью SEQ ID NO: 1. Изобретение также относится к вектору и к бактерии, которые экспрессируют указанный конъюгат. Настоящее изобретение относится к косметическим и фармацевтическим композициям, которые содержат указанный конъюгат и предназначены для лечения дерматологических заболеваний. Изобретение позволяет получать композиции для лечения дерматологических заболеваний. 12 н. и 11 з.п. ф-лы, 15 ил., 1 табл., 13 пр.

БИОЛОГИЧЕСКИ АКТИВНЫЕ ПРОИЗВОДНЫЕ АЛЛОФЕРОНА-1

Группа изобретений относится к медицине и касается применения производного Аллоферона-1 Phe(p-NH2)-Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly в качестве средства, обладающего высокой иммуномодулирующей и противовирусной активностью. Группа изобретений также касается иммуномодулирующей и противовирусной композиции, содержащей пептид Phe(p-NH2)-Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly или его фармацевтически приемлемые соли в сочетании со стандартными вспомогательными веществами. Группа изобретений обеспечивает стимулирование индукции интерлейкина-18, интерферона гамма и подавление вирусов гриппа А и В. 2 н.п. ф-лы, 4 пр., 4 табл.

ПРИМЕНЕНИЕ ПОСЛЕДОВАТЕЛЬНОСТИ ДНК, КОТОРАЯ КОДИРУЕТ ПЕПТИД, СПОСОБНЫЙ СВЯЗЫВАТЬСЯ С ТРАНСФОРМИРУЮЩИМ ФАКТОРОМ РОСТА β1 (ВАРИАНТЫ)

Изобретение относится к генной инженерии, конкретно к получению ингибиторов TGF-β1 и может быть использовано в медицине. ДНК, кодирующую пептид, способный связываться с TGF-β1, и ингибировать его биологическую активность in vitro и in vivo, применяют в качестве средства, ингибирующего биологическую активность TGF-β1. Изобретение позволяет эффективно лечить заболевания или патологические нарушения, связанные с гиперэкспрессией или разрегулированной экспрессией TGF-β1, за счет ингибирования биологической активности TGF-β1. 2 н. и 2 з.п. ф-лы, 6 ил., 4 табл., 4 пр.

БИЦИКЛИЧЕСКИЕ ПЕПТИДНЫЕ ЛИГАНДЫ, СПЕЦИФИЧНЫЕ ДЛЯ MT1-MMP

Изобретение относится к полипептидам, которые ковалентно связаны с молекулярными каркасами, так что две или более пептидные петли замыкаются между точками присоединения к каркасу. В частности, в изобретении описываются пептиды, которые связываются с высокой аффинностью с мембранной металлопротеазой типа 1 (MT1-MMP). В изобретении также описываются конъюгаты лекарств, включающие указанные пептиды, конъюгированные с одной или более эффекторными и/или функциональными группами, которые применяются в визуализации и таргетной терапии рака. 5 н. и 25 з.п. ф-лы, 13 ил., 17 табл., 5 пр.

АНТИБАКТЕРИАЛЬНЫЕ ПЕПТИДЫ

Настоящее изобретение относится к пептидам с антибактериальной и эндотоксиннейтрализующей активностью, имеющим общую формулу (Хаа)-(Хаа)-Хаа-(Хаа)-(Хаа)-(Хаа)-(Хаа)-(Хаа). 12 н. и 31 з.п. ф-лы, 7 ил., 6 табл., 10 пр.

ПЕПТИДЫ, ПРОНИКАЮЩИЕ В КЛЕТКУ

Изобретение относится к биотехнологии и представляет собой проникающий в клетку пептид для усиления прохождения гидрофильного физиологически активного вещества через слой эпителиальных клеток слизистой оболочки, а также фармацевтическую композицию, включающую вышеуказанный пептид. Проникающий в клетку пептид представляет собой пептид с аминокислотной последовательностью, представленной SEQ ID NO: 1, а также пептид с аминокислотной последовательностью, представленной SEQ ID NO: 1, и имеющий различные модификации, при этом этот пептид обладает способностью проникать через мембрану клеток. Предложенное изобретение позволяет усилить прохождение гидрофильного физиологически активного вещества через слой эпителиальных клеток слизистой оболочки и позволяет гидрофильному физиологически активному веществу проходить в общий кровоток. 4 н. и 4 з.п. ф-лы, 16 ил., 1 табл., 12 пр.

ПЕПТИД, ПОЛУЧЕННЫЙ ИЗ CDCA1, И СОДЕРЖАЩАЯ ЕГО ВАКЦИНА

Изобретение относится к эпитопным пептидам, полученным из CDCA1, со способностью индуцировать цитотоксические T-клетки. Настоящее изобретение дополнительно относится к полинуклеотидам, кодирующим пептиды, антигенпрезентирующим клеткам, презентирующим пептиды, и цитотоксическим T-клеткам, нацеленным на пептиды, а также к способам индуцирования антигенпрезентирующих клеток или ЦТЛ. Настоящее изобретение также относится к композициям и фармацевтическим композициям, содержащим их в качестве активного ингредиента. Дополнительно настоящее изобретение относится к способам лечения и/или профилактики злокачественной опухоли и/или профилактики ее послеоперационного рецидива с использованием пептидов, полинуклеотидов, антигенпрезентирующих клеток, цитотоксических T-клеток или фармацевтических композиций по настоящему изобретению. Также предлагаются способы индуцирования иммунного ответа против злокачественной опухоли. 12 н. и 6 з.п. ф-лы, 12 ил., 3 табл., 4 пр.

Пептид, обладающий лечебным действием против болезни Альцгеймера

Изобретение относится к области биохимии, конкретно - к новому биологически активному соединению – пептиду Ac-Ala-Trp-Lys-Val-Leu-Ser-Pro-Gln-Gly-Gly-Gly-Pro-Trp-Asp-Ser-Val-Ala-NH, обладающему более длительным терапевтическим действием против болезни Альцгеймера. 1 ил., 2 пр.

ПЕПТИД, СТИМУЛИРУЮЩИЙ ПРОТИВООПУХОЛЕВЫЙ ИММУННЫЙ ОТВЕТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ, СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩЕГО И СПОСОБ МОДУЛЯЦИИ ИММУННОГО ОТВЕТА

Изобретение относится к биотехнологии и медицине. Предлагаются пептид структуры TyrSerLeu, фармацевтическая композиция на его основе, которую используют для стимулирования противоопухолевого иммунного ответа, а также способы лечения млекопитающего и модуляции иммунного ответа. Предлагаемые изобретения расширяют арсенал средств для лечения раковых заболеваний. 4 н. и 16 з.п. ф-лы, 49 табл.

ПЕПТИДЫ И СПОСОБЫ ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА

Изобретение относится к области биотехнологии, конкретно к иммуногенным пептидам, и может быть использовано в медицине для лечения диабета 1 типа. Предложен иммуногенный пептид длиной от 17 до 50 аминокислот, содержащий последовательность CXX[CST]SLQPLALEGSLQK или [CST]XXCSLQPLALEGSLQK, где X представляет собой аминокислоту и где [CST] представляет собой один из C, S или T. Изобретение обеспечивает получение цитолитических CD4+T-клеток, которые характеризуются повышенной выработкой IFN-гамма и sFasL по сравнению с пептидами из уровня техники. 7 н. и 4 з.п. ф-лы, 2 ил., 2 табл., 6 пр.

ИММУНОГЕННЫЕ ПРОДУКТЫ, ПОЛУЧЕННЫЕ НА ОСНОВЕ АМИНОКИСЛОТНЫХ ПОСЛЕДОВАТЕЛЬНОСТЕЙ МУТЕИНОВОГО АМИЛОИДА β (Aβ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Настоящее изобретение относится к области иммунологии. Предложен иммуногенный продукт, который представляет собой усеченный мутеиновый олигомер Aβ для индуцирования иммунного ответа против амилоидоза, и композиция для лечения или предупреждения амилоидоза, содержащая такой продукт. Настоящее изобретение может найти дальнейшее применение в терапии болезни Альцгеймера или синдрома Дауна. 2 н. и 12 з.п. ф-лы, 4 ил., 10 табл., 13 пр.

НОВЫЕ ПРОТИВОБАКТЕРИАЛЬНЫЕ СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ ГРАМПОЛОЖИТЕЛЬНЫХ ИНФЕКЦИЙ

Изобретение относится к новым липопептидным соединениям формулы (I):и к его фармацевтически приемлемым солям, где: R представляет:и v представляет целое число от 3 до 5. Изобретение также относится к фармацевтической композиции, обладающей противобактериальной активностью, на основе указанного соединения. Технический результат: получено новое соединение формулы (I), которое может найти применение в медицине в качестве антибактериальных средств против. 5 н. и 21 з.п. ф-лы, 9 табл., 20 пр.

АНТИБИОТИЧЕСКИЕ ПЕПТИДЫ

Изобретение относится к новому антибиотическому пептиду и производным пептидов, в частности, для применения в медицине. Дополнительно, изобретение относится к композициям и к способу скринингового анализа лекарственных средств. Пептиды и производные пептида имеют общую формулу Sub-XNXXPVYIPXXRPPHP-Sub, где Sub, X, X, X, X, Subуказаны в формуле изобретения. Пептиды или производные пептидов по изобретению обладают по меньшей мере одним из следующих преимуществ по сравнению с пептидами апидецина, встречающимися в природе: (i) увеличенное время полужизни в сыворотке млекопитающих вследствие более высокой протеазной устойчивости, (ii) повышенная противомикробная активность по отношению к одному или нескольким бактериальным штаммам, в частности к патогенам человека, или грибам, или другим микробным инфекциям, (iii) демонстрируют расширенный спектр противомикробной активности, (iv) вызывают меньшее развитие устойчивости у микроорганизмов и (v) не являются токсичными для клеток человека, включая ...

ПЕПТИД ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА

Изобретение относится к медицине, а именно к неврологии, и может быть использовано для терапии болезни Альцгеймера. Предложено применение пептида общей формулы ацетил-D-LYS-Lys-ARG-ARG-амид для лечения болезни Альцгеймера. Использование изобретения позволяет достичь устойчивого ноотропного эффекта на скополамин-индуцированной модели болезни Альцгеймера. 8 табл., 14 ил., 3 пр.

АГОНИСТЫ АПОЛИПОПРОТЕИНА А-1 И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ДИСЛИПИДЕМИЧЕСКИХ НАРУШЕНИЙ

Изобретение относится к медицинской молекулярной биологии. Сущность изобретения составляют новые пептидные последовательности и их аналоги, обладающие свойствами агонистов аполипопротеина А-I (Аро-А-I) путем ввведения их эффективного количества пациенту. Такие пептиды и их аналоги используют для лечения разнообразных нарушений, связанных с дислипидемией. Изобретение содержит сведения о соответствующих химических структурах, различных комплексах таких пептидов, в частности, с липидами, фармацевтических композициях и методах лечения дислипидемических нарушений. Технический результат - расширение арсенала средств терапии различных дислипидемических состояний. 14 с. и 47 з.п.ф-лы, 10 табл., 10 ил.

НОВЫЕ ПРОТИВООПУХОЛЕВЫЕ СОЕДИНЕНИЯ

Настоящее изобретение связано с новыми противоопухолевыми соединениями кахалалида, в частности с аналогами кахалалида F, используемыми в качестве противоопухолевых агентов. 6 н. и 7 з.п. ф-лы, 6 табл.

МОДУЛЯЦИЯ СПЕЦИФИЧНОСТИ СТРУКТУРИРОВАННЫХ БЕЛКОВ

Изобретение относится к области биотехнологии, конкретно к пептидным лигандам человеческого плазматического калликреина, что может быть использовано в медицине. Путем скрининга библиотек мутантных пептидов получают лиганды к человеческому калликреину, библиотеки указанных лигандов и наборы библиотек указанных лигандов, отличающиеся тем, что полученный лиганд содержит аминокислотную последовательность WPAR. Изобретение позволяет получить лиганды к человеческому калликреину с повышенной специфичностью. 4 н. и 11 з.п. ф-лы, 16 ил., 22 табл., 6 пр.

ПРОИЗВОДНЫЕ КАХАЛАЛИДА F

Изобретение относится к новым противоопухолевым соединениям, представляющим собой производные кахалалида F, содержащим их фармацевтическим композициям и их применению для приготовления противоопухолевого лекарственного средства. 4 н.п. ф-лы, 11 табл.

ПЕПТИДЫ С БОЛЬШИМ ЧИСЛОМ МОСТИКОВЫХ СВЯЗЕЙ, ВЫДЕЛЯЕМЫЕ ИЗ ACTINOMADURA NAMIBIENSIS

Группа изобретений относится к биохимии. Предложены соединения лабиринтопептинов А1, А2, или А3 формулы (I), где {A}, {B}, {C}, R-R, m и n имеют значения, указанные в формуле изобретения. Соединения получают при ферментации штаммаDSM 6313 в приемлемых условиях в культуральной среде до образования одного или нескольких соединений формулы (I). Предложены ДНК, кодирующая препролабиринтопептин А2, и ДНК, кодирующая препролабиринтопептин А1, а также препролабиринтопептины А1 и А2, пролабиринтопептины А1 и А2. Лабиринтопептины формулы (I) применяют для лечения инфекций, вызываемых грамположительными бактериями, вирусных инфекций и/или невропатической боли, вызываемой воспалением. 11 н. и 13 з. п. ф-лы, 4 табл., 20 пр.

СТРУКТУРНЫЕ ПЕПТИДНЫЕ ИНГИБИТОРЫ АГРЕГАЦИИ α-СИНУКЛЕИНА

Изобретение относится к области биотехнологии, конкретно к ингибиторным пептидам α–синуклеина, и может быть использовано в медицине для ингибирования агрегации α–синуклеина. Предложен ингибиторный пептид до 30 аминокислот в длину, содержащий GAVVWGVTAVKK или RAVVTGVTAVAE. При этом по меньшей мере одна из аминокислот в ингибиторном пептиде представляет собой не встречающуюся в природе аминокислоту, выбранную из D–аминокислоты или аминокислоты, содержащей фрагмент N–метильной группы. Также ингибиторный пептид содержит гетерологичный пептидный тэг для повышения его растворимости, облегчения его мониторинга и/или вхождения пептида в клетку млекопитающего. Изобретение обеспечивает ингибирование образования, затравки фибрилл и распространения агрегатов aльфа-синуклеина. 2 н. и 2 з.п. ф-лы, 7 ил., 4 табл., 3 пр.

ПЕПТИД, ПОЛУЧЕННЫЙ ИЗ KOC1, И СОДЕРЖАЩАЯ ЕГО ВАКЦИНА

Изобретение относится к эпитопным пептидам, полученным из KOC1, со способностью индуцировать цитотоксические T-клетки. Настоящее изобретение дополнительно относится к полинуклеотидам, кодирующим пептиды, антигенпрезентирующим клеткам, презентирующим пептиды, и цитотоксическим T-клеткам, нацеленным на пептиды, а также к способам индуцирования антигенпрезентирующих клеток или ЦТЛ. Настоящее изобретение также относится к композициям и фармацевтическим композициям, содержащим их в качестве активного ингредиента. Дополнительно настоящее изобретение относится к способам лечения и/или профилактики злокачественной опухоли и/или профилактики ее послеоперационного рецидива с использованием пептидов, полинуклеотидов, антигенпрезентирующих клеток, цитотоксических T-клеток или фармацевтических композиций по настоящему изобретению. Также предлагаются способы индуцирования иммунного ответа против злокачественной опухоли. 12 н. и 7 з.п. ф-лы, 16 ил., 4 табл., 5 пр.

МОЛЕКУЛЯРНЫЕ КОНСТРУКЦИИ С НАЦЕЛИВАЮЩИМИ И ЭФФЕКТОРНЫМИ ЭЛЕМЕНТАМИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Изобретение относится к области биотехнологии. Описана группа изобретений, включающая линкерное звено, содержащее центральную сердцевину, связывающие ветви и, необязательно, соединяющую ветвь (варианты). В одном из вариантов линкерное звено содержит центральную сердцевину, которая содержит первый полипептид, содержащий лизиновые (K) остатки, где каждый и следующий за ним остаток K разделены вставочной последовательностью, содержащей глициновые и сериновые остатки, и полипептид имеет длину от 8 до 120 аминокислотных остатков и количество остатков K находится в диапазоне от 2 до 15; или второй полипептид, содержащий последовательность (Х-K), где каждый Хпредставляет собой пегилированную аминокислоту, имеющую от 2 до 12 повторяющихся этиленгликолевых звеньев, а n является целым числом от 2 до 15; связывающие ветви связаны с остатками K центральной сердцевины, где каждая из связывающих ветвей представляет собой цепь PEG, имеющую от 2 до 20 повторяющихся EG-звеньев. Изобретение расширяет арсенал ...

ПЕПТИДЫ НАПРАВЛЕННОГО ДЕЙСТВИЯ НА VEGFR-1/NRP-1

Изобретение относится к области молекулярной медицины и мишень-ориентированной доставки терапевтических средств. Предложены новые пептидные последовательности размером 10 или менее аминокислот, содержащие в своем составе по крайней мере непрерывную аминокислотную последовательность D(LPR), которые селективно воздействуют на клетки, экспрессирующие VEGFR-1 и NRP-1. Мишень-ориентированные молекулы в соответствии с данным изобретением пригодны для лечения и выявления неоваскулярных и ангиогенных VEGF-ассоциированных нарушений, например, таких как рак, ожирение, диабет, астма, артрит, цирроз и глазные болезни. 5 н. и 11 з.п. ф-лы, 4 ил, 2 пр.

ПЕПТИДНАЯ КОМПОЗИЦИЯ

Группа изобретений относится к области медицины, а именно к стабильной пептидной композиции, включающей: самособирающийся пептид; буферный агент, содержащий по меньшей мере одно вещество, выбранное из группы, состоящей из гистидина, нитрата тиамина, пиридина, бис-триса, этилендиамина и/или N-метилморфолина; и воду, при этом стабильная пептидная композиция имеет рН от 4,5 до 6,6; причем суммарный заряд аминокислотных остатков, содержащихся в самособирающемся пептиде, составляет между более 0 и +3 или менее в стабильной пептидной композиции; при этом С-конец самособирающегося пептида включает амидную группу; причем аминокислота на С-конце самособирающегося пептида включает основную аминокислоту; при этом самособирающийся пептид образован из следующей аминокислотной последовательности: a1b1c1b2a2b3db4a3b5c2b6a4, где каждый остаток a1-a4представляет собой основной аминокислотный остаток, каждый остаток b1-b6представляет собой незаряженный полярный аминокислотный остаток и/или гидрофобный аминокислотный ...

Способ получения высокоочищенного тетрадекапептида

Изобретение относится к пептидной и фармацевтической химии, а именно к способу получения тетрадекапептида H-Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu-OH реакцией конденсации пентапептида формулы Boc-Thr-Glu(OtBut)-Lys(Boc)-Lys(Boc)-Arg-OH с нонапептидом со свободной аминогруппой формулы H-Arg-Glu(OtBut)-Thr-Val-Glu(OtBut)-Arg-Glu(OtBut)-Lys(Boc)-Glu(OtBut)-OtBut, при этом пентапептид Вос-Thr-Glu(OtBut)-Lys(Boc)-Lys(Boc)-Arg-OH получают из аргинина путем последовательного присоединения к нему N-сукцинимидилового эфира Nα-карбобензокси-Nε-трет-бутилоксикарбонил-L-лизина, N-сукцинимидилового эфира Nα-карбобензокси-Nε-трет-бутилоксикарбонил-L-лизина, N-сукцинимидилового эфира Nα-карбобензокси-γ-трет-бутилглутаминовой кислоты и пентафторфенилового эфира N-трет-бутилоксикарбонил-L-треонина, а нонапептид получают конденсацией пентапептида Z-Glu(OtBut)-Thr-Val-Glu(OtBut)-ArgOH с трипептидом со свободной аминогруппой формулы H-Glu(OtBut)-Lys(Boc)-Glu(OtBut)-OtBut с последующей конденсацией ...

Вакцина против PCSK9

... 1. Иммуноген для индуцирования иммунного ответа против белка PCSK9, содержащий антигенный пептид PCSK9, выбранный из группы, состоящей из SEQ ID NO: 191-226, конъюгированный с иммуногенным носителем.2. Иммуноген по п. 1, где антигенный пептид PCSK9 конъюгирован с иммуногенным носителем, выбранным из CRM 197 или Qbeta вирусоподобной частицы (VLP).3. Иммуноген по п. 2, где антигенный пептид PCSK9 выбран из группы, состоящей из SEQ ID NO: 191-198.4. Иммуноген по п. 2, где антигенный пептид PCSK9 выбран из группы, состоящей из SEQ ID NO: 199-205.5. Иммуноген по п. 3 или 4, где указанный антигенный пептид PCSK9 дополнительно содержит любой из следующих:- на своем С-конце линкер, имеющий формулу (G)C, (G)SC или (G)K, где n представляет собой целое число, выбранное из группы, состоящей из 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 и 10,- на своем N-конце линкер, имеющий формулу C(G), CS(G)или K(G), где n представляет собой целое число, выбранное из группы, состоящей из 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 и 10, или ...

ИНГИБИТОРЫ USP30 И СПОСОБЫ ПРИМЕНЕНИЯ

... 1. Способ увеличения митофагии в клетке, включающий приведение клетки в контакт с ингибитором USP30.2. Способ увеличения митохондриального убиквитинирования в клетке, включающий приведение клетки в контакт с ингибитором USP30.3. Способ увеличения убиквитинирования по меньшей мере одного, по меньшей мере двух, по меньшей мере трех, по меньшей мере четырех, по меньшей мере пяти, по меньшей мере шести, по меньшей мере семи, по меньшей мере восьми, по меньшей мере девяти, по меньшей мере десяти, по меньшей мере одиннадцати, по меньшей мере двенадцати, по меньшей мере тринадцати или четырнадцати белков, выбранных из Tom20, MIRO, MUL1, ASNS, FKBP8, ТОМ70, МАТ2В, PRDX3, IDE, VDAC1, VDAC2, VDAC3, IP05, PSD13, UBP13 и РТН2 в клетке, включающий приведение клетки в контакт с ингибитором USP30.4. Способ по п. 3, где данный способ включает увеличение убиквитинирования по меньшей мере одной, по меньшей мере двух или трех аминокислот, выбранных из K56, K61 и K69 Tom 20.5. Способ по п. 3, где данный способ ...

КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ СМЕСЬ ИЗОФОРМ CD95-Fc

... 1. Композиция, включающая смесь изоформ слитых белков, каждый слитый белок, включающий, по меньшей мере, внеклеточный домен CD95 или его функциональный фрагмент и, по меньшей мере, Fc-домен или его функциональный фрагмент, распределенные в рамках pI-диапазона 4,0-8,5.2. Композиция по п. 1, в которой домен Fc представляет собой домен Fc человека.3. Композиция по п. 1, в которой слитый белок представляет собой APG101, полипептид, имеющий, по меньшей мере, 70% идентичности с APG101, и/или функциональный фрагмент APG101.4. Композиция по п. 1, в которой pI-диапазон равен 4,5-7,8, предпочтительно 5,0-7,5.5. Композиция по п. 1, включающая 0,0-5,0 мол.% высокомолекулярных форм слитого белка, таких как димеры и/или агрегаты.6. Композиция по п. 1, включающая высокие количества сиаловых кислот.7. Композиция по п. 3, включающая укороченные с N-конца слитые белки, такие как -17, -21 и/или -26 слитые белки,8. Композиция по п. 1 в которой домен Fc или его функциональный фрагмент гликозилирован по N-связи ...

ИММУНОДЕПРЕССАНТЫ

... 1. Соединение формулы II где, если позволяют валентность и стабильность, А отсутствует или обозначает последовательность, состоящую из одного-четырех аминокислотных остатков или остатков аминокислотных аналогов; В представляет собой последовательность, состоящую из двух-восьми аминокислотных остатков или остатков аминокислотных аналогов; W обозначает OR7 или NR8R9; V независимо в каждом случае обозначает С=O, C=S или SO2, X отсутствует или обозначает О, S или NR; R независимо в каждом случае обозначает Н или низший алкил; R1 обозначает замещенную или незамещенную алкильную, гетероалкильную, алкенильную, алкинильную, арильную, аралкильную, гетероарильную, гетероаралкильную, циклоалкильную, циклоалкилалкильную, гетероциклическую или гетероциклоалкильную группу; R2 обозначает замещенную или незамещенную алкильную, гетероалкильную, алкенильную, алкинильную, арильную, аралкильную, гетероарильную, гетероаралкильную, циклоалкильную, циклоалкилалкильную, гетероциклическую или гетероциклоалкильную ...

АНТИБАКТЕРИАЛЬНЫЕ И ПРОТИВОВИРУСНЫЕ ПЕПТИДЫ ИЗ ACTINOMADURA NAMIBIENSIS

... 1. Соединение формулы (I) !! где R1 представляет собой H, C(O)-(C1-C6)алкил или C(O)-O-(C1-C6)алкил; ! R2 представляет собой OH, NH2, NH-(C1-C6)алкил, NH-(C1-C4)алкилен-фенил или NH-(C1-C4)алкилен-пиридил; ! R3 и R4 независимо друг от друга представляют собой H или OH, или R3 и R4 вместе представляют собой =O; и ! m и n независимо друг от друга равны 0, 1 или 2; ! в любой стереохимической форме, или в смеси любых стереохимических форм при любом отношении, или его физиологически переносимая соль. ! 2. Соединение формулы (I) по п.1, представленное формулой (II) ! ! 3. Соединение формулы (I) по любому из пп.1 или 2, в котором R1 представляет собой H. ! 4. Соединение формулы (I) по п.1, в котором R2 представляет собой OH. ! 5. Соединение формулы (I) по п.1, в котором R3 и R4 представляют собой H или OH, где, если R3 представляет собой OH, тогда R4 представляет собой H, или если R3 представляет собой H, тогда R4 представляет собой OH, или R3 и R4 вместе представляют собой =O. ! 6. Соединение ...

ПЕПТИД, ОБЛАДАЮЩИЙ ВЫСОКОЙ АФФИННОСТЬЮ К БЕЛКУ PD-L1, И ЕГО ПРИМЕНЕНИЕ

Настоящее изобретение относится к области биотехнологии, конкретно к связывающим PD-L1 пептидам, и может быть использовано для получения антагониста белка PD-L1, для детекции или для клинического анализа экспрессии белка PD-L1. Изобретение обеспечивает получение пептида, способного связываться с человеческим PD-L1, с высокой аффинностью. 7 н.п. ф-лы, 6 ил.

СВЯЗЫВАЮЩИЙ АНТИТЕЛО ПОЛИПЕПТИД, СВЯЗЫВАЮЩИЙ АНТИТЕЛО ГИБРИДНЫЙ ПОЛИПЕПТИД И АДСОРБЦИОННЫЙ МАТЕРИАЛ

Изобретение относится к связывающему антитело полипептиду, представленному в любой из SEQ ID NO: с 1 по 18, и адсорбционному материалу для антитела или производного антитела, где связывающий антитело полипептид иммобилизован на водонерастворимом носителе. Эти связывающий антитело полипептид и адсорбционный материал имеют прекрасные связывающие антитело свойства и селективность в отношении антител, а также прекрасную устойчивость к щелочи и временную стабильность. 5 н. и 1 з.п. ф-лы, 2 табл., 25 пр.

Пептиды, связывающие фактор роста эндотелия сосудов

Изобретение относится к области биотехнологии, а именно, к соединениям, которые способны связывать фактор роста эндотелия сосудов (VEGF), и могут быть использованы в медицине. Данные соединения представляют собой спиральные пептиды, характеризующиеся наличием в определенных положениях аминокислотной последовательности Сα-тетразамещенной аминокислоты, в частности, α-аминоизобутановой кислоты, которая способствует усилению связывания с VEGF, а также повышает устойчивость пептидов к ферментативному расщеплению. 3 табл., 28 ил.

ВАКЦИННЫЕ КОНСТРУКТЫ И ИХ ПРИМЕНЕНИЯ ПРОТИВ ИНФЕКЦИЙ СТАФИЛОКОККА

ИНГИБИТОРЫ ПЕПТИДИЛАРГИНИНДЕЗИМИНАЗЫ (PAD)

... 1. Соединение, способное ингибировать активность PAD, содержащее пептидную часть и тиолреактивную электрофильную группу, которую несет аминокислота Ω, в котором ! (а) пептидная часть содержит по меньшей мере примерно 5 аминокислот и примерно не более 20 аминокислот, ! (b) пептид содержит по меньшей мере один из мотивов (b1), (b2), (b3) или (b4): ! (b1) G/S/T - D/S - Ω - D/G/S - G/S ! (b2) H/K/F/L/W - S/D/H - Ω - D/E - H/Y/F/W ! (b3) Y/A/K/H/L - F/Y/H - Ω - N/G/H/Y - K/A/F ! (b4) Y - D/S - Ω - D/G/S - G/S ! в котором Ω представляет аминокислоту, несущую тиолреактивную электрофильную группу, ! (c) необязательно N-конец и/или C-конец пептидной последовательности является модифицированным. ! 2. Соединение по п.1, в котором тиолреактивная электрофильная группа представляет собой галогенамидиновую группу, предпочтительно фторамидин или хлорамидин. ! 3. Соединение по п.1 или 2, в котором Ω представляет собой орнитин. ! 4. Соединение по п.1, в котором мотив, определенный в (b1), представляет собой ...

МАКРОЦИКЛИЧЕСКИЕ АНТИБИОТИКИ ШИРОКОГО СПЕКТРА ДЕЙСТВИЯ

КЛЕЩЕВОЙ АЛЛЕРГЕН ДОМАШНЕЙ ПЫЛИ

... 1. Полипептид, содержащий аминокислотную последовательность, имеющую по меньшей мере 60% идентичность с аминокислотной последовательностью SEQ ID No. 1, или содержащий по меньшей мере один аминокислотный фрагмент по меньшей мере из 6 последовательных аминокислотных остатков аминокислотной последовательности SEQ ID No. 1, или имеющий иммунологическую перекрестную реактивность с аминокислотной последовательностью SEQ ID No. 1 или ее фрагментами, где эта аминокислотная последовательность SEQ ID No. 1 кодирует (кодифицирует) аллерген, и этот полипептид содержит по меньшей мере один Т-клеточный эпитоп, узнаваемый Т-клеточным рецептором, специфическим в отношении молекулы, имеющей аминокислотную последовательность SEQ ID No. 1. ! 2. Полипептид по п.1, отличающийся тем, что указанная аминокислотная последовательность по меньшей мере на 70%, предпочтительно по меньшей мере на 80%, более предпочтительно по меньшей мере на 90%, наиболее предпочтительно по меньшей мере на 95%, в частности, на 100% ...

ЦИКЛИЧЕСКИЙ ПЕПТИД, ПОДЛОЖКА ДЛЯ АФФИННОЙ ХРОМАТОГРАФИИ, МЕЧЕНОЕ АНТИТЕЛО, КОНЪЮГАТ АНТИТЕЛА С ЛЕКАРСТВЕННЫМ СРЕДСТВОМ И ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ

CXCR4-РЕЦЕПТОРНЫЕ СОЕДИНЕНИЯ

... 1. Соединение, представленное формулой A:или его фармацевтически приемлемая соль, где: L является связывающей группой, представленной C(O) и связанной с N-концевым азотом группы Xили следующим присутствующим аминокислотным остатком, если Xотсутствует; T является липофильной привязывающей группой, связанной с L; и Rявляется ORили N(R), каждый Rявляется независимо H или алкилом,где присутствуют по меньшей мере три смежных X-Xаминокислотных остатка, и где:Xявляется валиновым остатком или отсутствует,Xявляется изолейциновым остатком или отсутствует,Xявляется лейциновым остатком или отсутствует,Xявляется валиновым остатком, глициновым остатком или отсутствует,Xявляется метиониновым остатком, изолейциновым остатком, лейциновым остатком, норлейциновым остатком, сериновым остатком, аланиновым остатком, d-метиониновым остатком, d-сериновым остатком или отсутствует,Xявляется глициновым остатком, аланиновым остатком, гистидиновым остатком, лизиновым остатком или отсутствует,Xявляется тирозиновым остатком ...

НОВЫЙ ПРОНИКАЮЩИЙ В КЛЕТКИ ПЕПТИД, ЕГО КОНЪЮГАТ С БОТУЛОТОКСИНОМ И ИХ ПРИМЕНЕНИЕ

АГОНИСТИЧЕСКИЕ АУТОАНТИТЕЛА К α- И β-АДРЕНЕРГИЧЕСКИМ РЕЦЕПТОРАМ ПРИ БОЛЕЗНИ АЛЬЦГЕЙМЕРА И СОСУДИСТОЙ ДЕМЕНЦИИ

... 1. Пептид, состоящий из:(i) аминокислотной последовательности SEQ ID NO 1: LGYWAFGRVFCN или SEQID NO 2: PAPEDETICQINEE);(ii) аминокислотной последовательности, идентичной аминокислотной последовательности (i) на 70%, предпочтительно на 80% или более предпочтительно на 90% или 95%;(iii) аминокислотной последовательности (i) или (ii), модифицированной путем разветвления или удлинения с помощью одного и того же или другого пептида аминокислотной последовательности (i) или (ii) с образованием гомоолигомерного или гетероолигомерного пептида,посредством чего любой конец пептида последовательностей (i)-(iii) имеет дополнительную группу, выбранную из аминовой, амидной, ацетильной, биотиновой, детиобиотиновой групп, маркера, спейсера, линкера, GKK, SGKK, или не имеет дополнительной группы.2. Пептид по п. 1 для применения в медицинской диагностике или в качестве лекарственного средства.3. Пептид по п. 1 или 2, отличающийся тем, что он связывается с антителами страдающих деменцией пациентов, предпочтительно ...

МОДУЛЯЦИЯ СПЕЦИФИЧНОСТИ СТРУКТУРИРОВАННЫХ БЕЛКОВ

... 1. Пептидный лиганд, специфичный к человеческому калликреину, содержащий полипептид, включающий по меньшей мере три реакционноспособные группы, разделенные по меньшей мере двумя последовательностями петель, и молекулярный каркас, который образует ковалентные связи с указанными реакционноспособными группами полипептида таким образом, что по меньшей мере две полипептидных петли образуются на указанном молекулярном каркасе, где указанные петли указанного пептидного лиганда содержат три, четыре или пять, но менее шести, аминокислот.2. Пептидный лиганд по п. 1, где указанные петли пептидного лиганда содержат три аминокислоты, и указанный полипептид имеет консенсусную последовательность GFxxGRVxG, где Gпредставляет собой реакционноспособную группу.3. Пептидный лиганд по п. 2, который включает один из полипептидов4. Пептидный лиганд по п. 1, где указанные петли пептидного лиганда содержат пять аминокислот, и первая петля содержит консенсусную последовательность GGGxxNG, где Gпредставляет собой ...

СОВМЕСТНАЯ ХИМИОТЕРАПИЯ И ИММУНОТЕРАПИЯ

... 1. Способ лечения опухоли у субъекта, включающий стадию: ! введение субъекту эффективного для лечения количества пептида EGFRvIII и эффективного для лечения количества химиотерапевтического средства, вызывающего лимфопению. ! 2. Способ по п.1, где химиотерапевтическое средство является алкилирующим средством. ! 3. Способ по п.1, где пептид EGFRvIII конъюгирован с гемоцианином лимфы улитки (KLH). ! 4. Способ по п.1, дополнительно включающий стадию: ! введение субъекту эффективного количества GM-CSF в качестве адъюванта одновременно с пептидом EGFRvIII. ! 5. Способ по п.1, где пептид EGFRvIII имеет последовательность H-LEEKKGNYVVTDHS-OH (SEQ ID NO: 1). ! 6. Способ по п.1, где пептид EGFRvIII имеет последовательность LEU-GLU-GLU-LYS-LYS-GLY-ASN-TYR-VAL-VAL-THR-ASP-HIS (SEQ ID NO: 2). ! 7. Способ по п.1, где пептид EGFRvIII имеет последовательность LEU-GLU-GLU-LYS-LYS-GLY-ASN-TYR-VAL-VAL-THR-ASP-HIS-CYS (SEQ ID NO: 3) и где KLH конъюгирован с остатком CYS. ! 8. Способ по п.7, где пептид EGFRvIII ...

СОЕДИНЕНИЯ ПЕПТИДНО-ОЛИГОМОЧЕВИННЫХ ФОЛДАМЕРОВ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СОСТОЯНИЙ ИЛИ ПРОЦЕССОВ, ХАРАКТЕРИЗУЮЩИХСЯ АБЕРРАНТНОЙ ПРОЛИФЕРАЦИЕЙ ФИБРОБЛАСТОВ И НАКОПЛЕНИЕМ ВНЕКЛЕТОЧНОГО МАТРИКСА

СУБСТРАТЫ МАТРИПТАЗЫ И U-АКТИВАТОРА ПЛАЗМИНОГЕНА И ДРУГИЕ РАСЩЕПЛЯЕМЫЕ ОСТАТКИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

ПЕПТИД, ПОЛУЧЕННЫЙ ИЗ KOC1, И СОДЕРЖАЩАЯ ЕГО ВАКЦИНА

ПЕПТИДНАЯ ВАКЦИНА ДЛЯ ПРЕДУПРЕЖДЕНИЯ И ИММУНОТЕРАПИИ ДЕМЕНЦИИ АЛЬЦГЕЙМЕРОВСКОГО ТИПА

ПЕПТИДЫ, ПРОНИКАЮЩИЕ В КЛЕТКУ

... 1. Проникающий в клетку пептид, который является любым от (A) до (D), указанных ниже:(А) пептид с аминокислотной последовательностью, представленной SEQ ID NO: 1;(В) пептид с аминокислотной последовательностью, такой же, что и аминокислотная последовательность, представленная SEQ ID NO: 1, за исключением того, что одна или несколько основных аминокислот замещены, удалены, вставлены и/или добавлены, где этот пептид обладает способностью проникать через мембрану клеток;(С) пептид с аминокислотной последовательностью, такой же, что и аминокислотная последовательность, представленная SEQ ID NO: 1, за исключением того, что от одной до пяти аминокислот замещены, удалены, вставлены и/или добавлены, где этот пептид обладает способностью проникать через мембрану клеток;(D) пептид с аминокислотной последовательностью, представленной обратной последовательностью любого от (A) до (C), где аминокислотная последовательность является такой же, как и аминокислотная последовательность, представленная обратной ...

ВАКЦИНА ПРОТИВ PCSK9

... 1. Иммуноген, содержащий по меньшей мере один антигенный пептид PCSK9 или его функционально активный вариант, связанный с иммуногенным носителем, где антигенный пептид PCSK9 выбран из группы, состоящей из SEQ ID NO:182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 317, 401, 402 и 403.2. Иммуноген, содержащий по меньшей мере один антигенный пептид PCSK9 или его функционально активный вариант, связанный с иммуногенным носителем, где антигенный пептид PCSK9 выбран из группы, состоящей из SEQ ID NO:46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 314, 318 и 319.3. Иммуноген по п.1 или 2, где указанный иммуногенный носитель выбран из дифтерийного ...

КОМПОЗИЦИИ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ ПЕПТИДОВ НЕОГЕНЕЗА ОСТРОВКОВ И ИХ АНАЛОГОВ

НОВЫЕ МОЛЕКУЛЫ-ИНГИБИТОРЫ JNK

... 1. Ингибитор JNK, выбранный из группы, включающей:а) ингибитор JNK, который содержит ингибирующую (поли)пептидную последовательность, имеющую следующую общую формулу:X1-X2-X3-R-X4-X5-X6-L-X7-L-X8 (SEQ ID NO: 1),в которой X1 обозначает аминокислоту, выбранную из аминокислот R, P, Q и r,в которой Х2 обозначает аминокислоту, выбранную из аминокислот R, P, G и r,в которой Х3 обозначает аминокислоту, выбранную из аминокислот К, R, k и r,в которой Х4 обозначает аминокислоту, выбранную из аминокислот Р и К,в которой Х5 обозначает аминокислоту, выбранную из аминокислот Т, a, s, q, k, или Х5 отсутствует,в которой Х6 обозначает аминокислоту, выбранную из аминокислот Т, D и А,в которой Х7 обозначает аминокислоту, выбранную из аминокислот N, n, r и К; ив которой Х8 обозначает аминокислоту, выбранную из аминокислот F, f и w,в которой аминокислотный остаток, обозначенный заглавными буквами, соответствует L-аминокислоте, а аминокислотный остаток, обозначенный прописными буквами, соответствует остатку ...

ИММУНОМОДУЛИРУЮЩИЕ СПОСОБЫ И СИСТЕМЫ ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРЕДОТВРАЩЕНИЯ АНЕВРИЗМ

... 1. Способ лечения и/или предотвращения аневризмы и/или ассоциированного с ней состояния у индивидуума, где способ включаетвведение индивидууму эффективного количества одного или нескольких из иммуногенных фрагментов ApoB-100 или их иммуногенно активной части, где иммуногенный фрагмент содержит одну из SEQ ID NO: 1-302, где один или несколько иммуногенных фрагментов или их иммуногенно активная часть ассоциированы с уменьшением атеросклероза.2. Способ по п.1, где один или несколько иммуногенных фрагментов содержат один или несколько пептидов, где каждый содержит одну из SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, SEQ ID NO:25, SEQ ID NO:45, SEQ ID NO:74, SEQ ID NO:99, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 129, SEQ ID NO: 143, SEQ ID NO: 148, SEQ ID NO:210 и SEQ ID NO:301.3. Способ по п.1, где один или несколько иммуногенных фрагментов содержат один или несколько пептидов, где каждый содержит одну из SEQ ID NO: 2, SEQ ID NO: 11, SEQ ID NO: 45, SEQ ID NO: ...

МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ

СПОСОБЫ ОБНАРУЖЕНИЯ ФОЛАТНОГО РЕЦЕПТОРА 1 В ОБРАЗЦЕ ПАЦИЕНТА

ИММУНОГЕННЫЙ ПЕПТИД ПРОТИВ СТРЕПТОКОККОВ ГРУППЫ А

КОМПОЗИЦИИ И СООТВЕТСТВУЮЩИЕ СПОСОБЫ ДЛЯ СЕЛЬСКОГО ХОЗЯЙСТВА

ПОЛИПЕПТИДЫ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ

СХЕМЫ ВВЕДЕНИЯ

ПЕПТИД, ПОЛУЧЕННЫЙ ИЗ KOC1, И СОДЕРЖАЩАЯ ЕГО ВАКЦИНА

ВАКЦИНА ПРОТИВ ПЕПТИДА CH3 IgE

... 1. Иммуноген, содержащий по меньшей мере один антигенный пептид IgE, связанный с иммуногенным носителем, где указанный антигенный пептид IgE состоит из аминокислотной последовательности, выбранной из группы, состоящей из SEQ ID NO: 312, 311, 313, 314, 315, 316, 317, 318, 319, 320,321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337,338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, ...

ПРОТИВОМИКРОБНЫЕ ПЕПТИДЫ, СОДЕРЖАЩИЕ АРГИНИН-И ЛИЗИН-СОДЕРЖАЩИЙ МОТИВ

... 1. Пептид, его вариант или его фармацевтически приемлемая соль, содержащие аминокислоты формулы I: , где I и m представляют собой целые числа от 0 до 10; n представляет собой целое число от 1 до 10; Х и Y, которые могут быть одинаковыми или разными, представляют собой аминокислоты, выбранные из группы, состоящей из гидрофобных аминокислот и/или катионных аминокислот, для применения в качестве фармацевтического средства. 2. Пептид по п.1, где Х и Y выбраны из группы катионных аминокислот, состоящей из орнитина, гистидина, аргинина и лизина. 3. Пептид по п.2, где Х и Y выбраны из аргинина и лизина. 4. Пептид по п.1, где Х и Y являются одинаковыми. 5. Пептид по п.4, где Х и Y представляют собой аргинин. 6. Пептид по любому из пп.1-5, содержащий от 3 до примерно 200 аминокислот. 7. Пептид по п.6, содержащий от 3 до 100 аминокислот. 8. Пептид по п.7, содержащий от 3 до 50 аминокислот. 9. Пептид по п.8, содержащий от 3 до 15 аминокислот. 10. Пептид по п.9, содержащий от 3 до 7 аминокислот. 11 ...

ХИМЕРНЫЕ АНТИГЕНЫ ДЛЯ ВАКЦИНЫ ПРОТИВ ВИРУСА ГЕПАТИТА С

... 1. Химерный антиген для вакцины против вируса гепатита C (HCV), содержащий a) первый сегмент, состоящий из области E2 (аминокислоты 408-540) полибелка HCV, b) второй сегмент, состоящий из области E1 (аминокислоты 190-222) полибелка HCV, и c) третий сегмент, состоящий из области Core (аминокислоты 1-50) этого белка, именно в таком порядке.2. Химерный вакцинный антиген по п. 1, в котором его аминокислотная последовательность выбрана из группы, состоящей из SEQ ID No. 10 (антиген Eq1) и SEQ ID No. 16 (антиген Eq1b).3. Вакцинный химерный антиген по п. 1, в котором его последовательность дополнительно содержит по меньшей мере один эпитоп, специфичный для хелперных T-лимфоцитов.4. Вакцинный химерный антиген по п. 3, в котором эпитоп, специфичный для хелперных T-лимфоцитов, представляет собой эпитоп неструктурных белков HCV.5. Химерный вакцинный антиген по п. 4, в котором неструктурный белок представляет собой NS3.6. Химерный вакцинный антиген по п. 5, в котором его аминокислотная последовательность ...

НОВЫЕ ДЕПСИПЕПТИДЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ

... 1. Композиция, включающая соединение формулы или его соль, где (a) R представляет собой 2-бутил, изопропил или 2-(2’-аминофенацил); (b) каждый из R1 и R6 независимо представляет собой гидридо или метил; (c) R2 представляет собой метил или –CH2CH2CH2R8; (d) R3 представляет собой метил или –CH2CH2CH2 CH2R9; (e) R4 представляет собой гидридо или метокси; (f) R5 представляет собой гидрокси или карбоксиамино; (g) каждый из R7, R8 и R9 независимо представляет собой амино, монозамещенный амино, дизамещенный амино, ациламино, уреидо, гуанидино, карбамоил, сульфонамино, тиоациламино, тиоуреидо, иминоамино или фосфонамино; (h) при условии, что, (1) когда R2 представляет собой –CH2CH2CH2R8, R7 является отличным от где R10 представляет собой амино, монозамещенный амино, дизамещенный амино, ациламино, уреидо, гуанидино, карбамоил, сульфонамино, тиоациламино, иминоамино или фосфонамино; (2) когда R2 представляет собой метил, R7 является отличным от где каждый из R11 и R12 представляет собой гидридо, ...

НАЦЕЛЕННЫЕ/ИММУНОМОДУЛИРУЮЩИЕ СЛИТНЫЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ

... 1. Полинуклеотидная последовательность, содержащая нуклеиновокислотную последовательность, кодирующую химерный слитый белок, содержащий по меньшей мере одну направляющую группировку для нацеливания на раковую клетку и по меньшей мере одну иммуномодулирующую группировку, противодействующую иммунной толерантности, где направляющая группировка и иммуномодулирующая группировка соединены аминокислотным спейсером с достаточной длиной, измеряемой количеством аминокислотных остатков, так, что обе группировки могут успешно связываться с их отдельными мишенями.2. Полинуклеотидная последовательность по п. 1, где иммуномодулирующая группировка специфически связывается с одной из следующих молекул: (1) трансформирущий фактор роста-бета (TGFβ), (2) лиганд запрограммированной гибели-1 (PD1), (3) 4-1BB, (4) инсулиноподобный фактор роста-1 (IGF-1) или (5) интерлейкин-6 (IL-6).3. Полинуклеотидная последовательность по п. 1, где направляющая группировка представляет собой антитело или его фрагмент, специфически ...

СПОСОБ ПОЛУЧЕНИЯ АЦИЛИРОВАННЫХ ПОЛИПЕПТИДОВ

... 1. Способ получения полипептида, включающего, по крайней мере, один остаток лизина, ацилированный в ε-аминогруппе, который включает следующие стадии: (i) культивирование клетки-хозяина, содержащей полинуклеотидную последовательность, кодирующую молекулу-предшественник указанного полипептида, в условиях, приемлемых для экспрессии указанной молекулы-предшественника, включающей требуемый полипептид и N-концевой удлиняющий сегмент, отщепляемый от требуемого полипептида в лизиновом сайте расщепления; (ii) отделение экспрессированной молекулы-предшественника от культурального бульона; (iii) избирательное ацилирование ε-аминогруппы, по крайней мере, одного остатка лизина в требуемом полипептиде без ацилирования ε-аминогруппы лизинового сайта расщепления в N-концевом удлиняющем сегменте; (iv) удаление N-концевого удлиняющего сегмента из ацилированной молекулы-предшественника ферментативным гидролизом и (v) выделение ацилированного полипептида приемлемыми способами. 2. Способ по п.1, в котором N-концевой ...

СИНТЕТИЧЕСКИЕ ПЕПТИДЫ И СПОСОБ ПРОФИЛАКТИЧЕСКОГО И ЛЕЧЕБНОГО ПРИМЕНЕНИЯ ПРИ ИНВАЗИИ И МЕТАСТАЗИРОВАНИИ РАКА

... 1. Олигопептид, содержащий олигопептидную последовательность, выбранную из группы, состоящей из а) олигопептидной последовательности, представленной SEQ ID NO: 2 или 6; б) олигопептида, способного индуцировать иммунный ответ против эпитопа SEQ ID NO: 2; в) олигопептидной последовательности длиной от 8 до 10 аминокислотных остатков, включающей любую из последовательностей а) или б); г) олигопептидной последовательности, включающей любую из последовательностей от а) до в), в которой один или более аминокислотных остатков заменены аминокислотами со сходньми зарядом, размером или характеристиками гидрофобности при условии, что олигопептидная последовательность обладает способностью блокировать инвазию и метастазирование раковых клеток; д) олигопептидной последовательности, включающей любую из последовательностей от а) до г), в которой аминокислотный остаток на N- или С-конце пропущен при условии, что олигопептидная последовательность обладает способностью блокировать инвазию и метастазирование ...

POLYPEPTID BOMBESIN ANTAGONISTEN

ANTIMIKROBIELLE POLYPEPTIDE

MYKOBAKTERIELLE REKOMBINANTEN UND PEPTIDE

PEPTIDE UND VERWANDTE MOLEKÜLE, DIE AN TALL-1 BINDEN

ANTIMIKROBIELLE BREITSPEKTRUM-VERBINDUNGEN UND VERFAHREN ZU DEREN VERWENDUNG

POLYPEPTID UND VERFAHREN ZU SEINER HERSTELLUNG.

Lineare Adhäsionsinhibitoren

Peptide für die Wechselwirkung mit alpha-helikalen Coiled-Coil-Strukturen und/oder Coiled-Coil-Sequenzen, davon abgeleitete Mittel und ihre Verwendung

APOLIPOPROTEIN A-I AGONISTEN SOWIE DEREN VERWENDUNG ZUR BEHANDLUNG DISLIPIDEMISCHER ERKRANKUNGEN

MODIFIZIERTE ZYTOKINE FÜR KREBS THERAPIE

Antikoagulierende Peptid-Alkohole.

Ribonukleotidreduktase-Hemmer.

CONTULAKIN-G, ANALOGA DAVON UND DEREN VERWENDUNG

Bergofungin peptide

Peptide of formula (I), referred to as bergofungin, is new: Ac Val Aib Aib Aib Val Gly Leu Aib Aib Hyp Gln Iva Hyp Aib Pheol (I) Aib = alpha -aminoisobutyric acid, Hyp = L-hydroxyproline, Iva = L-isovaline and Pheol = L-phenylalaninol.

TESTVERFAHREN ZUR MESSUNG DER PHOSPHORYLIERUNG

TACHYKININPEPTIDE, IHRE PRÄPEPTIDE UND SIE KODIERENDE GENE

DIE ERZEUGUNG EINER IMMUNANTWORT GEGEN ERWÜNSCHTE DETERMINANTEN

SCREENING-VERFAHREN

Biological control of nanoparticle nucleation, shape and crystal phase

The present invention includes compositions and methods for selective binding of amino acid oligomers to semiconductor and elemental carbon-containing materials. One form of the present invention is a method for controlling the particle size of the semiconductor or elemental carbon-containing material by interacting an amino acid oligomer that specifically binds the material with solutions that can result in the formation of the material. The same method can be used to control the aspect ratio of the nanocrystal particles of the semiconductor material. Another form of the present invention is a method to create nanowires from the semiconductor or elemental carbon-containing material. Yet another form of the present invention is a biologic scaffold comprising a substrate capable of binding one or more biologic materials, one or more biologic materials attached to the substrate, and one or more elemental carbon-containing molecules attached to one or more biologic materials.

Antibiotic peptides

The invention relates to a peptide or peptide derivative having the general formula: Sub 1 -X 1 -D 2 K 3 -P 4 -P 5 -Y 6 -L 7 -P 8 -R 9 -P 10 -X 2 -P 12 -P 13 -R 14 -X 3 -I 16 -P 17 /Y 17 -N 18 -N 19 -X 4 -Sub 2 , wherein X 1 is a non-polar, hydrophobic group or a positively charged group, D 2 is asparagine or glutamine, K 3 , X 2 , and X 4 are positively charged groups, X 3 is a positively charged group, proline, or a proline derivative; L 7 and I 16 are non-polar, hydrophobic groups, Y 6 and Y 17 are tyrosine, R 9 and R 14 are arginine, N 18 and N 19 are asparagine or glutamine, P 4 , P 5 , P 8 , P 10 , P 12 , P 13 , and P 17 are proline, hydroxyproline, or derivatives thereof, wherein possibly one or two of the groups selected from D 2 , P 4 , P 5 , P 8 , P 10 , P 12 , P 13 , P 17 , and Y 17 are replaced by an arbitrary group and/or P 13 and R 14 are exchanged, Sub 1 is the free or modified N-terminus, and Sub 2 is the free or modified C-terminus. The invention further relates to the use of the peptides and peptide derivatives in medicine, as an antibiotic, in a disinfectant or cleaning agent, as a preservative or in a packaging material, in pharmaceutical research, or in a screening method.

Apj receptor compounds

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.

Irak kinase family as novel target and biomarker for alzheimer

The present invention relates to methods and devices for the diagnosis or drug response prediction of neurological disorders by measuring kinase activity and studying the phosphorylation levels and profiles in samples of said patients. Furthermore the present invention relates to methods of identifying drug compounds relevant to neurological disorders by measuring kinase activity and studying phosphorylation levels. Also, the present invention relates to the use of inhibitors of the IRAK protein kinase family or a pharmaceutical composition thereof in the treatment of neurological disorders such as Alzheimer's disease.

Stabilized alpha helical peptides and uses thereof

Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.

Methods for preventing and treating angioedema

One aspect of the present invention provides a method of treating or preventing angioedema in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. One aspect of the present invention provides a method of treating or preventing vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R.

Methods of administering pif agonist peptides and uses thereof

A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a T H 2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection. Further, polyclonal antibodies against PIF peptides were generated that serve for precise measurements of PIF in biological fluids. They document pregnancy presence and viability as well it helps for monitoring pregnancies at risk in humans as well as in farm and non farm animals, improving animal husbandry, where currently no specific pregnancy test exists. Also the PIF antibodies may have additional therapeutic properties for treatment of HIV, and malaria.

Ligand-specific non-antibody compounds that inhibit cr2 activation and methods of use thereof

The present invention describes a novel non-antibody ligand-specific compound that selectively binds to a complement receptor type 2 (CR2) protein, a ligand thereof, or both, wherein the compound competitively inhibits CR2 ligand's binding to a CR2 protein in a standard assay. The present invention also describes compositions and methods of use thereof.

Protein conjugate having an endopeptidase- cleavable bioprotective moiety

The invention is directed to a procoagulant conjugate having an endopeptidase-activatable procoagulant protein moiety and one or more bioprotective moieties, which are conjugated to one another by a linker that is cleaved by an endopeptidase in situ to release the bioprotective moiety. The invention is also directed to therapeutic uses of the procoagulant conjugate and methods of making the conjugate.

Peptide

The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell. In particular, the present invention provides a peptide comprising or consisting of the sequence EDNIMVTFRNQASR. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia.

Skin Permeating And Cell Entering (SPACE) Peptides and Methods of Use Thereof

The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.

Detection and quantification of modified proteins

The invention provides a method detecting and quantifying proteins by mass spectrophotometric analysis using peptide internal standards and provides a highly sensitive way of detecting protein modifications. In one aspect, the invention provides a method for determining a site of ubiquitination in a polypeptide and for evaluating ubiquitination targets in a population of polypeptides. In this way, a proteome ubiquitination map can be obtained which comprises information relating to the ubiquitination states of a plurality of cellular polypeptides. Maps can be obtained for a variety of different types of cells and cell states. For example, ubiquitination targets in normal and diseased cells can be evaluated. Preferably, the map is stored as data files in a database. Individual ubiquitinated polypeptides identified can be used to generate molecular probes diagnostic of a cell state and/or can serve as targets for agents that modulate one or more cellular processes.

Zona pellucida binding peptides, expression vectors, compositions, and methods for species-specific immunocontraception of animals

Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals. The disclosed compositions may include immunogenic compositions or vaccines.

Novel compounds for inhibiting eef-2 kinase activity

The present invention discloses novel compounds for inhibiting eEF2 kinase and methods of use thereof.

Isolating biological modulators from biodiverse gene fragment libraries

The present invention provides a method for identifying a modulator or mediator of a biological activity, which activity includes antigenicity and or immunogenicity, said method comprising the step of: (i) producing a gene fragment expression library derived from defined nucleotide sequence fragments; and (ii) assaying the expression library for at least an amino acid sequence derived from step (i) for a biological activity wherein that activity is different from any activity the amino acid sequence may have in its native environment.

Complex of a protein comprising zinc oxide-binding peptides and zinc oxide nanoparticles, and use thereof

The present invention relates to a complex of a protein comprising zinc oxide-binding peptides and zinc oxide nanoparticles, to the use thereof as a drug delivery carrier for manufacturing medicines, and to a vaccine composition and a contrast agent comprising the composite. The protein comprising zinc oxide-binding peptides significantly improves the in vivo availability of zinc oxide-binding peptides, and therefore the complex of the present invention can be used not only as a drug delivery carrier for in vivo drug delivery or intracellular drug delivery, but also for in vivo imaging or cell imaging. The complex can be used for producing separating agents for effectively separating biological materials, therapeutic agents for hyperthermia, etc., contrast agents for MRI, and beads applicable to biosensors.

Unstructured recombinant polymers and uses thereof

The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.

Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods

The present invention relates to TIMP-3 binding compositions, methods of producing such compositions, and methods of using such compositions, including in the treatment of various conditions.

Polypeptides having modulatory effects on cells

The present invention relates to peptides and polypeptides having the sequence SAVTFAVCAL or variants thereof, capable of binding to Calcineurin and/or to NS5A-TP2 and to their use in therapy, as well as to nucleic acid sequences and vectors encoding these peptides and polypeptides, and to cells comprising said polypeptides, nucleic acid sequences or vectors. The invention further relates to the use of the peptides, polypeptides or their derivatives to bring about phenotypic changes in mammalian cells, particularly to up-regulate calcineurin activity. The invention finally relates to a method for intracellular identification of substances which bind to calcineurin and which modulate the physiological effects of calcineurin.

Use of pedf-derived polypeptides for promoting stem cells proliferation and wound healing

Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 80% amino acid sequence identity to SEQ ID NO: 1, and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. Also disclosed herein are compositions containing the synthetic peptide and applications thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in promoting stem cells proliferation or wound healing.

Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides

The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.

Inhibitors of Atypical Protein Kinase C and Their Use in Treating Hedgehog Pathway-Dependent Cancers

Methods and compositions are provided for modulating Hedgehog (Hh) pathway signaling in a cell. Aspects of the methods include methods for inhibiting Hh pathway-promoted cancer proliferation and/or metastasis that is promoted by Hh pathway signaling, methods for treating cancers promoted by Hh pathway signaling, and methods for screening candidate agents for the ability to treat a cancer promoted by Hh pathway signaling. In addition, reagents and kits thereof that find use in practicing the subject methods are provided.

Attachment of biological targeting groups using metal free click chemistry

The present invention relates to the field of polymer chemistry and more particularly to click-functionalized targeting compounds and methods for using the same.

Peptide bfp4 for promoting osteogenesis or vascularization and use thereof

Disclosed are a peptide for promoting osteogenesis and vascularization, and the use thereof. The peptide has a low molecular weight so that it can be economically produced. In addition, it promotes osteoblastic differentiation, thus inducing osteogenesis. Further, the peptide can promote the expression of VEGF, resulting in vascularization. Accordingly, the peptide is useful for the prophylaxis or therapy of ischemic diseases.

Methods for detection of botulinum neurotoxin

Provided herein is a large immuno-sorbent surface area assay (ALISSA) for rapid and sensitive detection of toxin or enzyme activity. This assay is designed to capture a low number of toxin or enzyme molecules and to measure their intrinsic protease activity via conversion of a fluorigenic or luminescent substrate. The ALISSA is significantly faster and more sensitive than methods routinely utilized in the art. This assay is applicable for use for detection of a variety of toxins or enzymes having proteolytic activity, such as botulinum neurotoxin, bacillus anthracis lethal factor, human chitinases, and aspergillus fumigatus proteases. Also provided are methods for constructing and identifying novel luminescent or fluorescent substrates suitable for use with the ALISSA method.

Artificial peptide and use thereof

Disclosed is a method for transforming human or non-human mammalian stem cells by introducing a desired peptide motif into the stem cells. The stem cell transformation method disclosed herein uses a synthesized peptide having an amino acid sequence which constitutes the desired peptide motif on the N-terminal end or C-terminal end of a cell membrane-permeable nucleolar localization signal sequence defined by the amino acid sequence KKRTLRKNDRKKR (SEQ ID NO:1).

Hair-binding peptides

Hair-binding peptides were isolated for their use in a variety of personal care formulations and applications. The isolation of hair-binding peptides was accomplished by enrichment using mRNA-display selection technology. Hair care compositions comprising peptide-based reagents prepared comprising the hair-binding peptides are also provided.

PEPTIDES MIMICKING HIV-1 VIRAL EPITOPES IN THE V2 LOOP FOR THE GP120 SURFACE ENVELOPE GLYCOPROTEIN

The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1. 1. An isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120 which binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection , does not react with blood of matched patients who did not receive the vaccine , and can , therefore , elicit anti-HIV-1 antibodies which protect against HIV-1 infection.2. The isolated immunogenic peptide of claim 1 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 1.3. The isolated immunogenic peptide of claim 2 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 7.4. The isolated immunogenic peptide of claim 2 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 11.5. The isolated immunogenic peptide of claim 2 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 12.6. The isolated immunogenic peptide of claim 2 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 13.7. The isolated immunogenic peptide of claim 2 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 14.8. The isolated immunogenic ...

PEPTIDES, CONJUGATES AND METHOD FOR INCREASING IMMUNOGENICITY OF A VACCINE

The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease. 1. A conjugate , comprising a peptide conjugated to an antigen , immunogen or to a vehicle comprising an antigen or immunogen , wherein the peptide comprises:(i) at least 10 amino acid residues of SEQ ID NO:3 that comprise the amino acid sequence GITELKKL; or,(ii) an amino acid sequence having at least 80% sequence identity with an amino acid sequence as provided under (i) and wherein the peptide, when subjected to serum samples from at least 10 human subjects that had been vaccinated with tetanus toxoid is in at least 50% of the serum samples bound by antibodies from the serum samples, as determined in a Tettox ELISA;wherein the peptide is not the tetanus toxin beta chain.2. The conjugate according to claim 1 , wherein the peptide comprises less than 100 amino acid residues.3. The conjugate according to claim 1 , wherein the antigen claim 1 , the immunogen or the vehicle comprising the antigen or immunogen is conjugated to the C-terminus of the peptide.4. The conjugate according to claim 1 , wherein 2 to 20 peptides are bound to the antigen claim 1 , immunogen or the vehicle comprising the antigen or immunogen.5. A pharmaceutical composition comprising a conjugate according .6. A method for prevention or treatment of cancer or an infectious disease in a subject claim 1 , comprising administering to a subject in need thereof a conjugate according to .7. (canceled)8. The method according to claim 6 , wherein the subject has antibodies against tetanus toxin or tetanus toxoid.9. The method according ...

Secreted Protein Acidic and Rich in Cysteine (SPARC) Protein SRM Assay

The current disclosure provides for specific peptides from the Secreted Protein Acidic and Rich in Cysteine (SPARC) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying SPARC directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. SPARC protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of SPARC peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. 1. A method for measuring the level of the Secreted Protein Acidic and Rich in Cysteine (SPARC) protein in a biological sample , comprising detecting and/or quantifying the amount of one or more modified or unmodified SPARC fragment peptides in a protein digest prepared from said biological sample using mass spectrometry; and calculating the level of modified or unmodified SPARC protein in said sample; andwherein said level is a relative level or an absolute level.20. The method of claim , further comprising the step of fractionating said protein digest prior to detecting and/or quantifying the amount of one or more modified or unmodified SPARC fragment peptides.34-. (canceled)5. The method of claim 1 , wherein said protein digest comprises a protease digest.68-. (canceled)9. The method of claim 1 , wherein the SPARC fragment peptide comprises an amino acid sequence as set forth as SEQ ID NO:1 claim 1 , SEQ ID NO:2 claim 1 , SEQ ID NO:3 claim 1 , SEQ ID NO:4 claim 1 , SEQ ID ...

IGA-BINDING PEPTIDE AND PURIFICATION OF IGA USING THE SAME

This invention relates to: a peptide which comprises an amino acid sequence consisting of 12 to 18 amino acid residues represented by (X)—C—(X)—C—(X) wherein each X independently represents an arbitrary amino acid residue other than cysteine, and C represents a cysteine residue, and is capable of binding to human IgA; and to a method for analyzing or purifying human IgA using the peptide. 118-. (canceled)19. A peptide which comprises an amino acid sequence consisting of 12 to 18 amino acid residues represented by the following formula I and is capable of binding to human IgA:{'br': None, 'sub': 1-3', '8-10', '1-3, '(X)—C—(X)—C—(X)\u2003\u2003(I)'}wherein each X independently represents an arbitrary amino acid residue other than cysteine; and C represents a cysteine residue.20. The peptide according to claim 19 , wherein the peptide comprises an amino acid sequence consisting of 16 to 18 amino acid residues represented by the following formula II and is capable of binding to human IgA:{'br': None, 'sub': 3', '7-9', '3, '(X)—C-L-(X)—C—(X)\u2003\u2003(II)'}wherein each X independently represents an arbitrary amino acid residue other than cysteine; C represents a cysteine residue; and L represents a leucine residue, and wherein the 9th and 10th amino acid residues Xs counted from the N terminus in the case that the number of amino acid residues of the peptide is regarded as 18 amino acid residues, each independently represent an arbitrary amino acid residue other than cysteine, or either of the 9th and 10th amino acid residues Xs, or both, are deleted.21. The peptide according to claim 19 , wherein the peptide comprises an amino acid sequence consisting of 16 to 18 amino acid residues represented by the following formula II and is capable of binding to human IgA:{'br': None, 'sub': 3', '7-9', '3, '(X)—C-L-(X)—C—(X)\u2003\u2003(II)'}wherein each X independently represents an arbitrary amino acid residue other than cysteine; C represents a cysteine residue; and L ...

Method for prepairing peptide inhibitors of a lipid-activated enzyme and peptides produced by same

The present invention is based on the discovery of a mechanism mediating the formation of amyloid-type aggregates of lipid-activated enzymes. The invention discloses a method for preparing inhibitors of said enzymes and provides peptide inhibitors having potential for therapeutic use. The method comprises the identification of aggregation-prone regions in the amino acid sequence of the enzyme by the use of a suitable computer algorithm and designing a peptide based on the found aggregation-prone region. 1. A method for preparing peptide inhibitors of a lipid-activated enzyme , the method comprising the steps of:a) identifying aggregation-prone regions in amino acid sequence of said enzyme by the use of a suitable computer algorithm;b) designing a peptide based on the aggregation-prone region found in step a), wherein said peptide comprises the sequence of said region or a part thereof;c) synthesizing the peptide designed in step b); andd) contacting the peptide obtained in step c) with said lipid-activated enzyme and measuring the activity of said enzyme, wherein said peptide is an inhibitor of said enzyme, if the activity of the enzyme is decreased in the presence of said peptide.2. The method according to claim 1 , wherein said lipid-activated enzyme is selected from the group consisting of phospholipases claim 1 , myeloperoxidase claim 1 , acid sphingomyelinase claim 1 , heat shock protein 70 and PAF acetylhydrolase.3. The method according to claim 2 , wherein said lipid-activated enzyme is bee-venom phospholipase A2 and the peptide designed in step b) is SYFVGKMYFNLI (SEQ ID NO:2).4. The method according to claim 2 , wherein said lipid-activated enzyme is phospholipase A2 in human tears and the peptide designed in step b) is TKFLSYK (SEQ ID NO:3).10. A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:1-68.11. The peptide according to comprising amino acid sequence KMYFNLI (SEQ ID NO:1).12. The peptide according to ...

PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC COMPOSITIONS COMPRISING SAID PEPTIDES

The present invention provides cancer peptides related to rapid replication and shared among different histological cancer types. The peptides are provided in compositions for interfering with replication in cancer, in preventive and therapeutic vaccines, and in diagnostic applications. The compositions for interfering with replication in cancer are useful for preventing and treating different histological types of cancer including ectodermic, endodermic, and mesodermic cancers as well as cancers arising in association with HIV. 1. A composition for interfering with replication of cancer comprising at least one sequence of SEQ ID NO(s): 1-203.2. The composition of comprising at least one peptide consisting essentially of at least one of SEQ ID NO(s): 1-203.3. The composition of comprising a mixture of at least two peptides of SEQ ID NO(s): 1-27 claim 1 , SEQ ID NO(s): 28-52 claim 1 , SEQ ID NO(s): 53-103 claim 1 , SEQ ID NO(s): 104-148 claim 1 , SEQ ID NO(s): 149-165 claim 1 , and SEQ ID NO(s): 166-203.4. The composition of comprising a protein comprising at least one sequence of SEQ ID NO(s): 1-203.5. The composition of claim 1 , wherein said composition is for direct or indirect interference with replication of cancer.6. The composition of claim 5 , wherein said composition is for indirect interference with cancer where the indirect interference is mediated by an immune response.7. An isolated or synthesized protein fragment or peptide comprising at least one of SEQ ID NO(s): 1-203 or a sequence sharing at least 70% identity with at least one of SEQ ID NO(s): 1-203.8. The isolated or synthesized protein fragment or peptide of consisting essentially of a peptide of at least one of SEQ ID NO(s): 1-203.9. The isolated or synthesized protein fragment or peptide of consisting of at least one of SEQ ID NO(s): 1-203.10. A vaccine comprising at least one of SEQ ID NO(s): 1-27 claim 7 , SEQ ID NO(s): 28-52 claim 7 , SEQ ID NO(s): 53-103 claim 7 , SEQ ID NO(s): 104-148 ...

PHENOLIC BINDING PEPTIDES

The present application relates to peptides which bind to tannin, polyphenolic or anthocyanin compounds, and particularly to tea and wine stains on a fabric or other surface. The invention also concerns binding peptide conjugates which includes a binding peptide coupled to an agent and the use of the binding peptide conjugate for delivering an agent to a desired target. 1. A binding peptide comprising an amino acid sequence shown in any one of SEQ ID NOs. 1-316 and a binding peptide having at least 70% sequence identity thereto.2. (canceled)3. The binding peptide of claim 1 , wherein the peptide is selected from the group consisting of KTPSPHG (SEQ ID NO. 1); PNTTRHS (SEQ ID NO. 2); LWTSPQL (SEQ ID NO. 8); TNNTSPT (SEQ ID NO. 24); SPTSTNS (SEQ ID NO. 43); TTTTPFA (SEQ ID NO. 77); SWNTSPL (SEQ ID NO. 80); QAVKASHATMYL (SEQ ID NO. 97); SYDLIPPRSGLA (SEQ ID NO. 104); DPNTTSH (SEQ ID NO.118); KASHLVP (SEQ ID NO: 132); LPTSTLT (SEQ ID NO. 139); QNQKSTT (SEQ ID NO. 158); SIIPPRQ (SEQ ID NO. 168); WSNKPLSPNDLR (SEQ ID NO. 193) and peptides having at least 75% amino acid sequence identity thereto.4. The binding peptide of claim 1 , having a repeatable motif selected from the group consisting ofLPL (SEQ ID NOs. 120, 123, 115 and 250);FAT (SEQ ID NOs. 125, 227 and 235);STT (SEQ ID NOs. 90, 158, 230 and 310);HSP (SEQ ID NOs. 18, 252 and 307);TNK (SEQ ID NOs. 40, 259 and 287);SPL (SEQ ID NOs. 53, 80, 152, 229, 232 and 292);THS (SEQ ID NOs. 62, 209 and 290);TSP (SEQ ID NOs. 8, 24, 80, 223 and 291);SPT (SEQ ID NOs. 24, 43 and 266);AQT (SEQ ID NOs. 59, 134 and 205);NSS (SEQ ID NOs. 31, 86, 213, 227 and 278);PAL (SEQ ID NOs. 109, 224 and 256);SGL (SEQ ID NOs. 104, 284 and 298); andTQT (SEQ ID NOs. 105, 281 and 287) and a binding peptide having the repeatable motif and at least 75% amino acid sequence identity to a binding peptide having the repeatable motif and listed herein.5. The binding peptide of claim 1 , wherein said peptide binds to a compound selected from the group ...

Treatments for Gastrointestinal Disorders

The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms. 183-. (canceled)84. A peptide or a pharmaceutically acceptable salt thereof , wherein the peptide comprises the amino acid sequence{'sub': 1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17, 'XaaXaaXaaXaaCysXaaXaaXaaCysAsnProAlaCysXaaGlyXaaXaa, or a pharmaceutically acceptable salt thereof; wherein'}{'sub': '1', 'Xaais Asn, D-Asn, Gln, D-Gln, Pro, Ala, n-Ala, D-Ala, Val, D-Val, Gly, Thr, D-Thr, Asp, D-Asp, γ-carboxylated Asp, Glu, D-Glu, γ-carboxylated Glu, α-aminosuberic acid (Asu), α-aminoadipic acid (Aad), α-aminopimelic acid (Apm), or is absent;'}{'sub': '2', 'Xaais Asp, γ-carboxylated Asp, Glu, γ-carboxylated Glu, Asu, Aad, Apm, or is absent;'}{'sub': '3', 'Xaais Asp, γ-carboxylated Asp, Glu, γ-carboxylated Glu, Asu, Aad, Apm, or is absent;'}{'sub': '4', 'Xaais Cys or D-Cys;'}{'sub': '6', 'Xaais P-Ser, P-Thr, P-homo-Ser, 4-hydroxyvaline phosphate, P-homo-Thr, P-Cys or P-Tyr;'}{'sub': '7', 'Xaais Tyr, Leu, Phe or Ile;'}{'sub': '8', 'Xaais Cys or D-Cys;'}{'sub': '14', 'Xaais Thr, Ala or Phe;'}{'sub': '16', 'Xaais Cys or D-Cys; and'}{'sub': '17', 'Xaais Tyr, D-Tyr, or is absent;'}wherein:{'sub': 1', '1, 'if Xaais present, Xaamay be modified on its amino group by methyl, ethanedioic acid, propanedioic acid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid or octanedioic acid;'}{'sub': 1', '2', '2, 'if Xaais absent and Xaais present, then Xaamay be modified on its amino group by methyl, ethanedioic acid, propanedioic acid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid or octanedioic acid; or'}{'sub': 1', '2', '3, 'if both Xaaand Xaaare ...

Method for the identification of t cell epitopes

A novel method to identify relevant T-cell epitopes recognized by CD8 + or CD4 − T lymphocytes is described. The method is based on the use of mRNA fragments synthesized from cDNA encoding portions of a polypeptide of interest. mRNA fragments are introduced into antigen-presenting cells to deduce an epitope's localization in a polypeptide of interest, such as a protein antigen.

BINDING PARTNERS OF ANTIBODIES SPECIFIC FOR DENDRITIC CELL ANTIGENS

The present invention relates to the field of diagnostics, therapeutics and immunological reagents. More particularly, the present invention provides binding partners of antibodies specific for dendritic cell (DC) antigens. The present invention further provides diagnostic and/or therapeutic agent based on the binding partners or antibodies specific for the binding partners. 2. The isolated peptide of comprising an amino acid sequence selected from AQKYQ (SEQ ID NO: 2) or APKQQ (SEQ ID NO: 3).3. The isolated peptide of comprising the amino acid sequence set forth in SEQ ID NO: 2.4. The isolated peptide of comprising the amino acid sequence set forth in SEQ ID NO: 10.5. The isolated peptide of consisting of the amino acid sequence set forth in SEQ ID NO: 10.6. The peptide of for use in generating antibody which specifically binds CMRF44 antigen.7. The peptide of for use in screening for antibodies which specifically bind CMRF44 antigen.8. The peptide of for use in assessing binding specificity of a CMRF44-like antibody.9. The peptide of for use as a release agent in a method for selection of CMRF44 expressing cells. This application is a divisional application of U.S. patent application Ser. No. 11/721,425, filed Jan. 8, 2009, which is U.S. National Phase of International Application PCT/AU2005/001864, filed Dec. 9, 2005 designating the U.S. and published in English as WO 2006/060871 on Jun. 15, 2006, which claims priority to Australian Patent Application No. 2004907069 filed Dec. 10, 2004.1. Field of the InventionThe present invention relates generally to the field of diagnostics, therapeutics and immunological reagents. More particularly, the present invention provides binding partners of antibodies specific for dendritic cell (DC) antigens. The present invention further provides diagnostic and/or therapeutic agents based on the binding partners or antibodies specific for the binding partners.2. Description of the Prior ArtReference to any prior art in this ...

CONTROL OF GROWTH AND REPAIR OF GASTRO-INTESTINAL TISSUES BY GASTROKINES AND INHIBITORS

A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease and gastric ulcers. 117-. (canceled)18. An inhibitor of a protein , the protein selected from a group of isolated homologous cellular growth stimulating proteins designated gastrokines , because the proteins are produced by gastric epithelial cells , the protein comprising a consensus amino acid sequence selected from the group consisting of VKE(K/Q)KXXGKGPGG(P/A)PPK(SEQ ID NO: 10) , VKE(K/Q)KLQGKGPGG(P/A)PPK(SEQ ID NO: 25) and VKE(K/Q)KGKGPGG(P/A)PPK(SEQ ID NO: 26) , and the inhibitor is selected from the group of peptides having an amino acid sequence consisting of KKTCIVHKMKK(SEQ ID NO: 14) and KKEVMPSIQSLDALVKEKK(SEQ ID NO: 15).19. A pharmaceutical composition used for the treatment of a gastro-intestinal disorder claim 18 , the composition comprising a growth stimulating peptide with a consensus sequence as in and derived from a gastrokine protein.20. A pharmaceutical composition for the treatment of diseases associated with overgrowth of gastric epithelia claim 18 , the compositions comprising an inhibitor according to .21. The pharmaceutical composition of claim 20 , wherein diseases are diseases of the colon and small intestine claim 20 , the diseases are selected from the group consisting of ulcerative colitis and Crohn's Disease.22. An isolated cDNA molecule encoding a human protein claim 20 , the protein having the amino acid ...

Light-Sensitive Ion-Passing Molecules

The invention provides polynucleotides and methods for expressing light-activated proteins in animal cells and altering an action potential of the cells by optical stimulation. The invention also provides animal cells and non-human animals comprising cells expressing the light-activated proteins.

Hyaluronic Acid Decomposition-Promoting Factor and Inhibitor Thereof

The present invention is directed to KIAA1199, which is a novel factor involved in decomposition of hyaluronic acid, and to use thereof. More specifically, the invention is directed to a hyaluronic acid decomposition-promoting agent containing the KIAA1199 gene and a protein encoded by the gene; to a hyaluronic acid decomposition-inhibiting agent characterized by inhibiting the activity or expression thereof (including an siRNA or a monoclonal antibody); and to a method for screening a novel hyaluronic acid decomposition-controlling agent, in which the method contains employing the expression of KIAA1199 as an index. 1. A method for screening a hyaluronic acid decomposition-controlling agent , wherein the method comprises assessing a hyaluronic acid decomposition controlling effect of a test substance by use of cells in which a KIAA1199 gene is highly expressed transiently or stably.2. The method according to claim 1 , wherein the hyaluronic acid decomposition controlling effect of the test substance is assessed on the basis of the expression level of the KIAA1199 gene or a protein encoded by the KIAA1199 gene as an index.3. The method according to claim 1 , which comprises the following steps:1) culturing cells in the presence or absence of the test substance;2) determining the expression level of the KIAA1199 gene or a protein encoded by the KIAA1199 gene in the cells; and3) assessing the hyaluronic acid decomposition controlling effect of the test substance on the basis of the difference between the expression level of the KIAA1199 gene or the protein encoded by the KIAA1199 gene in the cells determined in the presence of the test substance and that determined in the absence of the test substance.4. The method according to claim 1 , which comprises the following steps:1) culturing cells in coexistence with a labeled hyaluronic acid in the presence or absence of the test substance;2) recovering a culture supernatant after culturing, and determining a molecular ...

Peptides or Antibodies Which Bind to Melanoma Inhibitory Activity (MIA) Protein

The present invention relates to peptides and antibodies which bind to melanoma inhibitory activity protein and the uses of such peptides and antibodies. The invention also relates to nucleic acids coding for such peptides or antibodies. The invention also relates to pharmaceutical compositions comprising such peptides or antibodies or such nucleic acids. The present invention also relates to small molecule compounds which bind to melanoma inhibitory activity protein and to uses of such small molecule compounds. Moreover, the present invention also relates to a method of preventing dimerization and/or aggregation of melanoma inhibitory activity (MIA) protein. The invention is based on the identification of the relevant sites of interaction of the MIA protein with the inhibitory peptides/antibodies. Considering the amino acid sequence of this protein deprived from the signalling peptide, the residues involved in the interaction are selected from: A7, K53, G54, R55, R57, L58, F59, V64, Y69, R85, D87, K91, and more preferably C17, S18, Y47, G61, G66, D67, L76, W102, D103, C106. 122-. (canceled)23. A peptide or antibody that binds to melanoma inhibitory activity (MIA) protein and prevents dimerization and/or aggregation thereof , which peptide is not SEQ ID NO:46 or 47 , wherein binding of said peptide to MIA protein occurs at a surface of said MIA protein formed by at least three amino acid residues of said MIA protein selected from cysteine 17 , serine 18 , tyrosine 47 , glycine 61 , glycine 66 , aspartate 67 , leucine 76 , tryptophan 102 , aspartate 103 , cysteine 106 , valine 64 , tyrosine 69 , aspartate 87 , lysine 91 , glycine 54 , leucine 58 , phenylalanine 59 , alanine 7 , lysine 53 , arginine 55 , arginine 57 , arginine 85 , and lysine 94 , preferably cysteine 17 , serine 18 , tyrosine 47 , glycine 61 , glycine 66 , aspartate 67 , leucine 76 , tryptophan 102 , aspartate 103 , cysteine 106 , alanine 7 , lysine 53 , arginine 55 , arginine 57 , arginine 85 and ...

BONE MORPHOGENIC PROTEIN BINDING PEPTIDE

A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis. 125-. (canceled)26. An article of manufacture comprising an implant , wherein said implant has a surface , and wherein said surface includes a peptide having the amino acid sequence of SEQ ID No. 13 , or a fragment thereof , wherein said peptide or fragment increases the degree or rate of osteogenesis or calcification in vertebrates.27. The article of manufacture of wherein the implant further includes one or more of TGF-beta claim 26 , BMP-2 claim 26 , BMP-4 claim 26 , BMP-7 or demineralized bone matrix.28. The article of manufacture of wherein the implant further includes mesenchymal stem cells.29. The article of manufacture of wherein the implant further includes chondrogenic or osteogenic precursor cells.30. The article of manufacture of wherein the mesenchymal stem cells secrete one or more growth factors.31. The article of manufacture of wherein the growth factor is a TGF-beta family member.32. The article of manufacture of wherein the chondrogenic or osteogenic precursor cells secrete one or more growth factors.33. The article of manufacture of wherein the growth factor is a TGF-beta family member.34. The article of manufacture of wherein said implant is formed into the shape of a pin claim 26 , screw claim 26 , plate claim 26 , or prosthetic joint.35. The article of manufacture of wherein said peptide is immobilized on the surface of said implant.36. An article of manufacture comprising a solid support claim 26 ...

LINEAR IGE PEPTIDE EPITOPES OF HAZELNUT ALLERGEN COR A 1 AND CELERY ANTIGEN API 1

Linear polypeptide epitopes of hazelnut cor a 1 and celery api 1.0101 allergen of a sequence length of ten to fifteen amino acids for treatment and prevention of hazelnut or celery allergy are provided. Means and methods for diagnosing hazelnut or celery allergy, and for detecting hazelnut or celery allergens in a sample, are also provided. 2. A polypeptide molecule according to claim 1 , for the treatment or prevention of hazelnut allergy.3. A pharmaceutical composition comprising one or more polypeptide molecule species according to claim 1 , for the treatment or prevention of hazelnut allergy.4. A polypeptide molecule having a sequence length of 10 claim 1 , 11 or 12 amino acids claim 1 , said polypeptide molecule having an amino acid sequence comprised as a contiguous sequence in SEQ ID 001 claim 1 , for use as a medicament.5. A polypeptide molecule having a sequence length of 10 claim 1 , 11 claim 1 , 12 claim 1 , 13 claim 1 , 14 or 15 amino acids claim 1 , said polypeptide molecule having an amino acid sequence comprised as a contiguous sequence in SEQ ID 012 claim 1 , SEQ ID 013 or SEQ ID 014 claim 1 , for the treatment or prevention of celery allergy.6. A pharmaceutical composition comprising one or more polypeptide molecule species as set forth in claim 4 , for the treatment or prevention of celery allergy.7. A method of diagnosing allergy against celery and/or hazelnut in a patient claim 4 , comprising the steps of{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'providing a polypeptide molecule having a sequence length of 10, 11, 12, 13, 14 or 15 amino acids, said polypeptide molecule having an amino acid sequence comprised as a contiguous sequence in any of the sequences of ,'}contacting said polypeptide molecule with a patient sample comprising IgE molecules ex-vivo under conditions allowing for the specific binding of IgE molecules to IgE epitopes, anddetermining whether said polypeptide molecule is specifically bound by an IgE molecule comprised in ...

Inhibitors of protein kinases and uses thereof

Compounds that are capable of inhibiting the activity of one or more protein kinases are provided. The compounds are short, predominantly basic peptidic compounds comprising between about 5 and about 20 amino acids, and can optionally comprise an ATP mimetic moiety. The protein kinase inhibiting compounds can be used to inhibit the activity of one or more protein kinases in vitro or in vivo. Also provided are methods of inhibiting a protein kinase in a subject by administration of an effective amount of a protein kinase inhibiting compound and the use of the protein kinase inhibiting compounds, alone or in combination with other chemotherapeutic agents, in the treatment of protein kinase mediated diseases and disorders.

Compounds And Their Use

The present invention relates to peptides and their use in the treatment of microbial infections, in particular bacterial infections. In particular, the invention relates to peptides wherein at least 75% of the amino acids of the peptide are arginine and phenylalanine amino acids, at least 50% of the amino acids being arginine amino acids and at least 15% of the amino acids being phenylalanine amino acids. 1. A peptide wherein at least 75% of the amino acids of the peptide are arginine and phenylalanine amino acids , at least 50% of the amino acids being arginine amino acids and at least 15% of the amino acids being phenylalanine amino acids.2. The peptide of consisting of arginine and phenylalanine amino acids and zero to five non-arginine and non-phenylalanine substitutions.3. The peptide of comprising one or more substitution selected from the group consisting of lysine claim 2 , proline claim 2 , glycine and histidine.4. The peptide of consisting of arginine claim 3 , phenylalanine and one of the group consisting of lysine claim 3 , proline claim 3 , glycine and histidine.5. The peptide of consisting of arginine and phenylalanine amino acids.6. The peptide of comprising 3 to 200 amino acids.7. The peptide of consisting of 3 to 200 amino acids.8. The peptide of comprising an amino acid sequence selected from the group RRRFRFFFRFRRR (SEQ ID NO:) claim 6 , HHHFRFFFRFRRR (SEQ ID NO: 2) claim 6 , KKFPWRLRLRYGRR (SEQ ID NO: 3) claim 6 , RRRRRFFFRFRRR (SEQ ID NO: 4) claim 6 , RRRFRFRFRFRRR (SEQ. ID NO: 5) claim 6 , RRRFRFPFRFRRR (SEQ ID NO: 6) claim 6 , RRFRRFFFRRFRR (SEQ ID NO: 7) claim 6 , RRRRFFFRRRR (SEQ ID NO: 8) claim 6 , RRRRFRFRRRR claim 6 , (SEQ ID NO: 9) claim 6 , RRRRFPFRRRR (SEQ ID NO: 10) claim 6 , RRFRRRFRRFR (SEQ ID NO: 11) claim 6 , RRFRRRFRRFG (SEQ ID NO: 12) claim 6 , RRFGRRFRRFG (SEQ ID NO; 13) claim 6 , RRFRRFRRRFG (SEQ ID NO: 14) claim 6 , RRFRRFRRRFR (SEP ID NO: 15) claim 6 , FRRRRFFFRFRRR (SEQ ID NO: 16) claim 6 , RRRRRFFFRRRRF (SEQ ID NO: 17) ...

METHODS FOR SELECTIVE TARGETING

A selective targeting method is disclosed comprising contacting a library of ligands, particularly a peptide library, with an anti-target to allow the ligands to bind to the anti-target; separating the non-binding ligands from the anti-target bound ligands, contacting the non-binding anti-target ligands with a target allowing the unbound ligands to bind with the target to form a target-bound ligand complex; separating the target-bound ligand complex from ligands which do not bind to the target, and identifying the target-bound ligands on the target-bound ligand complex wherein the target-bound ligands have a Kin the range of about 10to 10M. Additionally claimed are the ligands identified according to the method. 1. A method for screening a peptide library comprising the steps of ,(a) contacting the peptide library with an anti-target to allow the peptides to bind with said anti-target;(b) separating unbound peptides;(c) contacting the unbound peptides with a selected target to allow said unbound peptides to bind with the target to form a target-bound peptide complex;(d) separating said target-bound peptide complex from peptides which do not bind to said target; and(e) identifying the target-bound peptides on the target-bound peptide complex.2. The method according to claim 1 , wherein step (a) claim 1 , (b) claim 1 , (c) or (d) is repeated between 2 to 10 times.3. (canceled)4. The method according to claim 1 , wherein said contacting step is in vivo.5. The method according to claim 1 , wherein said contacting step is in vitro.6. The method according to claim 1 , wherein the target-bound peptides bind with a selectivity corresponding to at least 10:1 and have a Kin the range of at least about 10M.7. The method according to claim 1 , wherein kis about 10secor less.8. The method according to claim 1 , wherein the identifying step comprises amplifying a nucleic acid coding for the target-bound peptide in a polymerase chain reaction.9. The method according to claim 1 , ...

EZRIN ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER

A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4+SEQ ID No.5, SEQ ID No.6+SEQ ID No.7 and SEQ ID No.8. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer. 1. An epitope comprising the amino acid sequence of SEQ ID No.1 , SEQ ID No.2 , SEQ ID No.3 , SEQ ID No.4+SEQ ID No.5 , SEQ ID No.6+SEQ ID No.7 , or SEQ ID No.8.2. The epitope of claim 1 , wherein the epitope comprises the amino acid sequence of SEQ ID No.1.3. The epitope of claim 1 , wherein the epitope comprises the amino acid sequence of SEQ ID No.2.4. The epitope of claim 1 , wherein the epitope comprises the amino acid sequence of SEQ ID No.3.5. The epitope of claim 1 , wherein the epitope comprises the amino acid sequence of SEQ ID No.4+SEQ ID No.5.6. The epitope of claim 1 , wherein the epitope comprises the amino acid sequence of SEQ ID No.6+SEQ ID No.7.7. The epitope of claim 1 , wherein the epitope comprises the amino acid sequence of SEQ ID No.8.8. An isolated antibody directed against the epitope of .9. The antibody of claim 8 , wherein the antibody is a monoclonal antibody.10. An isolated peptide comprising an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID No.1 claim 8 , SEQ ID No.2 claim 8 , SEQ ID No.3 claim 8 , SEQ ID No.4+SEQ ID No.5 claim 8 , SEQ ID No.6+SEQ ID No.7 claim 8 , or SEQ ID No.8 claim 8 , wherein the peptide has at most 10 additional amino acid residues on either side of the amino acid sequence.11. The peptide of claim 10 , wherein the peptide comprises the amino acid sequence of SEQ ID No.1.12. The peptide of claim 10 , ...

Antibacterial and antifungal peptides

This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.

WOUND HEALING PEPTIDES AND METHODS OF USE THEREOF

The current invention relates to methods and compositions for the treatment of wounds in a mammalian subject. Particularly, the invention relates to novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. A method to promote wound healing in a subject in need thereof , comprising administering to the subject a peptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-13.9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. (canceled)18. (canceled)19. (canceled)20. (canceled)21. (canceled)22. (canceled)23. (canceled)24. (canceled)25. (canceled)26. The method of claim 8 , wherein the peptide is administered in an amount effective to enhance the rate of migration of keratinocytes or endothelial cells claim 8 , or a combination of keratinocytes and endothelial cells claim 8 , towards a wound edge.27. The method of claim 8 , wherein the administration of the peptide results in an increase in the re-epithelialization of the wound.28. The method of claim 8 , wherein the administration of the peptide results in an increase in angiogenesis in or near the wound.29. The method of claim 8 , wherein the peptide is administered at a wound site.30. The method of claim 8 , wherein the wound is a thermal claim 8 , chronic claim 8 , acute or surgical wound.31. The method of claim 8 , further comprising administering to the subject a second agent.32. The method of claim 31 , wherein the second agent is a polypeptide.33. The method of claim 31 , wherein the second agent is a growth factor claim 31 , cytokine claim 31 , or enzyme.34. The method of claim 31 , wherein the second agent is a non-human collagenase.35. The method of claim 34 , wherein the non-human collagenase is bacterial collagenase.36. The method of ...

Usp2a peptides and antibodies

The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment.

Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling

A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.

GM1-LIKE PEPTIDES AND USES THEREOF

Compositions and methods relating to interfering with the interaction of gangliosides, such as GM1, with their ligands are provided. For example, methods are provided for treating infections by blocking the infectious agent from binding with GM1 using GM1-like peptides. Also provided are methods of inhibiting ligands from binding to GM 1 on the surface of cells and for neutralizing anti-GM1 antibodies in neurological diseases. 1. A peptide comprising SEQ ID NO:1 , SEQ ID NO:2 , SEQ ID NO:3 , SEQ ID NO:4 , SEQ ID NO:5 , or SEQ ID NO:6 , or a sequence comprising the amino acids of SEQ ID NO:1 , SEQ ID NO:2 , SEQ ID NO:3 , SEQ ID NO:4 , SEQ ID NO:5 , or SEQ ID NO:6 having one or more conservative substitutions.2. The peptide of claim 1 , wherein the peptide inhibits binding of a ligand to GM1 ganglioside.3. The peptide of claim 2 , wherein the ligand is an antibody or a bacterial protein.4. The peptide of wherein the peptide consists of SEQ ID NO:1 claim 1 , SEQ ID NO:2 claim 1 , SEQ ID NO:3 claim 1 , SEQ ID NO:4 claim 1 , SEQ ID NO:5 claim 1 , or SEQ ID NO:6.5. A composition comprising a peptide of .6. The composition of claim 5 , wherein the peptide mimics the carbohydrate epitope of GM1.7. The composition of claim 5 , wherein the peptide binds cholera toxin B subunit.8. The composition of claim 5 , wherein the peptide binds anti-GM1 antibodies.9. The composition of claim 5 , further comprising a therapeutic agent.10. The composition of claim 5 , further comprising a detectable agent.11. The composition of claim 1 , wherein the peptide is 50 amino acids or less.12. A method of inhibiting binding of a ligand to GM1 comprising administering an effective amount of a GM1-like peptide.13. The method of claim 12 , wherein the ligand is a bacterial protein.14. The method of claim 13 , wherein the bacterial protein is cholera toxin B subunit.15E. coli. The method of claim 13 , wherein the bacterial protein is heat-labile enterotoxin.16. The method of claim 12 , wherein the ...

Methods for treating or preventing vascular graft failure

The described invention provides pharmaceutical compositions and methods for treating or preventing vascular graft failure in a subject in need of such treatment, the method comprising administering a therapeutically effective amount of a composition comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof, and a pharmaceutically acceptable carrier. The methods also are clinically useful for treating a pre-atherosclerotic intimal hyperplasia condition.

PEA PROTEIN PEPTIDES WITH ANTI HELICOBACTER PYLORI ACTIVITY

The invention relates to a composition comprising pea protein hydrolysate for the treatment and/or prevention of infection by gastrointestinal pathogens, in particular and/or a disease associated with infection by said gastrointestinal pathogen in mammals. 120.-. (canceled)21. A method for treatment and/or prevention of infection by gastrointestinal pathogens and/or a disease associated with infection by gastrointestinal pathogens in a mammal , comprising administering to the mammal a composition comprising pea protein hydrolysate obtained by hydrolysis with a protease other than chymotrypsin.22. The method according to claim 21 , wherein the pea protein hydrolysate is obtained by hydrolysing the pea protein legumin A or vicilin.23. The method according to claim 21 , wherein the pea protein hydrolysate is obtained by hydrolysis by the protease trypsin.24. The method according to claim 21 , wherein the pea protein hydrolysate comprises over 35 wt % peptides with a size of between 1 and 2.5 kDa based on total weight of the pea protein hydrolysate.25Helicobacter, Escherichia coli, Salmonella, Campylobacter, Porhyromonos gingivalis, ClostridiumEnterobacter.. The method according to claim 21 , wherein the gastrointestinal pathogen is selected from the group consisting of and26Helicobacter.. The method according to claim 25 , wherein the pathogen is27Helicobacter pylori.. The method according to claim 26 , wherein the pathogen is28. The method according to claim 21 , wherein the disease associated with infection is selected from the group consisting of gastritis claim 21 , peptic ulcer and gastric cancer.29. The method according to claim 21 , wherein the mammal is (i) an infant with the age between 0 and 5 years or (ii) a patient suffering from gastroduodenal diseases.30. The method according to claim 21 , wherein the mammal has been treated with one or more antibiotics.31. A method for treatment and/or prevention of infection by gastrointestinal pathogens and/or a ...

RFamide-Related Peptides and Methods Thereof

Provided herein methods and compositions directed to RFRP-1 polypeptides for modulating cardiac contractile function, for preventing and/or treating cardiac disorders.

Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.

TARGETED NON-INVASIVE IMAGING PROBES OF EGFR EXPRESSING CELLS

A probe for imaging EGFR expressing cells includes an EGFR targeting moiety, a reporter moiety, and a hydrophilic linker that links the EGFR targeting moiety to the reporter moiety. The hydrophilic linker enhances solubility of the probe in an aqueous media as well as binding affinity of the probe to EGFR expressing cells. 1. A probe for imaging EGFR expressing cells , comprising:an EGFR targeting moiety,a reporter moiety, anda hydrophilic linker that links the EGFR targeting moiety to the reporter moiety, the hydrophilic linker enhancing solubility of the probe in an aqueous media as well as binding affinity of the probe to EGFR expressing cells.2. The probe of claim 1 , EGFR targeting moiety comprising a peptide having SEQ ID NO: 1 or SEQ ID NO: 2.3. The probe of claim 1 , the reporter moiety comprising a fluorochrome.4. The probe of claim 1 , the linker comprising a polyethylene glycol linker.5. The probe of claim 1 , upon systemic administration to subject being capable of crossing the blood brain barrier.6. The probe of claim 1 , the EGFR expressing cells comprising EGFR expressing cancer cells.8. A probe for imaging EGFR expressing cells claim 1 , comprising:a hydrophobic EGFR targeting moiety,a reporter moiety, anda hydrophilic linker that links the hydrophobic EGFR targeting moiety to the reporter moiety, the hydrophilic linker enhancing solubility of the probe in an aqueous media as well as binding affinity of the probe to EGFR expressing cells.9. The probe of claim 8 , EGFR targeting moiety comprising a peptide having SEQ ID NO: 1 or SEQ ID NO: 2.10. The probe of claim 9 , the reporter moiety comprising a fluorochrome.11. The probe of claim 9 , the linker comprising a polyethylene glycol linker.12. The probe of claim 9 , upon systemic administration to subject being capable of crossing the blood brain barrier.13. The probe of claim 9 , the EGFR expressing cells comprising EGFR expressing cancer cells.15. A probe for imaging EGFR expressing cells claim 9 , ...

Borrelia antigens

The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from Borrelia , a vector comprising such nucleic acid molecule, a host cell comprising such vector, a protein, preferably a hyperimmune serum-reactive antigen from Borrelia , a process for producing such protein, a process for producing a cell which expresses such protein, an antibody that binds to such protein, a hybridoma cell producing such antibody, a method for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, or antibody, use of such nucleic acid molecule, protein, or antibody for the manufacture of a medicament, a method for identifying an antagonist capable of reducing or inhibiting the activity of such protein, a method for diagnosis or treatment of an infection with a pathogen causing Lyme disease or an infection with Borrelia burgdorferi s.l.

S. EPIDERMIDIS ANTIGENS

Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of infections, are disclosed. 1. An isolated hyperimmune serum-reactive antigen consisting of a fragment of SEQ ID NO: 52 , wherein said fragment comprises an amino acid sequence selected from the group consisting of amino acids 89-94 , 102-115 , 123-129 , 181-188 , 200-206 , 211-235 , 239-249 , 267-281 , 295-310 , 316-321 , 331-341 , 344-359 , 365-386 , 409-422 , 443-453 , 495-506 , 514-521 , 539-547 , 553-560 , 563-570 , 586-596 , 621-626 , 633-638 , 651-657 , 666-683 , 697-705 , 731-739 , 761-768 , 865-883 and 213-265 of SEQ ID NO: 52 , and wherein said fragment is less than 892 amino acids in length.2. An immunogenic composition comprising the isolated hyperimmune serum-reactive antigen of .3. The immunogenic composition of claim 2 , comprising at least 2 different hyperimmune serum-reactive antigens.4. The immunogenic composition of claim 2 , further comprising an adjuvant.5. The immunogenic composition of claim 3 , further comprising an adjuvant.6. A fusion protein comprising the hyperimmune serum-reactive antigen according to .7. An immunogenic composition comprising the fusion protein of .8. The immunogenic composition of claim 7 , further comprising an adjuvant.9. A method of inducing an immune response in a subject comprising:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'administering the immunogenic composition of to a subject;'}wherein an immune response is induced in the subject.10. The method of claim 9 , wherein the subject is a human.11S. epidermidis. The method of claim 9 , wherein the subject has an infection.12. A method of inducing an immune response in a subject comprising:{'claim-ref': {'@idref': 'CLM-00007', 'claim 7'}, 'administering the immunogenic composition of to a subject;'}wherein an immune response is induced in the subject.13. The method of claim 12 , wherein ...

NOVEL SIGNAL PEPTIDE, AND USE THEREOF FOR PRODUCING RECOMBINANT PROTEINS

A use of a signal peptide for producing a recombinant polypeptide of interest in an expression system, the signal peptide includes at least 12 amino acids of formula (I): 1. A method for producing a recombinant polypeptide of interest in an expression system , comprising introducing a signal peptide into the expression system , said signal peptide comprising at least 12 amino acids of formula (I):{'br': None, 'sub': 'i', '(X1)X2X3X4SX5X6X7,'} X1 is a peptide containing from 3 to 6 amino acids, i equal to 0 or 1,', 'X2 is a peptide containing from 3 to 9 hydrophobic amino acids,', 'X3 is a peptide containing from 3 to 5 amino acids, said peptide comprising at least 3 contiguous or non-contiguous leucines', 'X4 is a peptide containing from 2 to 5 amino acids chosen from Ala, Thr, Ser, Gln, Ile, Met,', 'X5 is Ala or Val,', 'X6 is Gln, Asn or His,', 'X7 is Ala or Cys,, 'in which when said signal peptide originates from a natural precursor of a specific protein, said polypeptide of interest is different from said protein, and', 'when the signal peptide is MAWVWTLLFLMAAAQSAQA, said polypeptide of interest is not an anti-CD23 antibody, irrespective of the polypeptide of interest which can be bound to one of said signal peptides in order to be secreted in the extracellular medium., 'provided that2. The method according to claim 1 , in which the quantity of the secreted polypeptide corresponds at least to the quantity of said secreted polypeptide using its natural signal peptide.3. The method according to claim 1 , in which said universal signal peptide is represented by the formula (II):{'br': None, 'i': 'i', 'M(X1)X2X3X4SX5X6X7,'}in which X1, i, X2, X3 X4, X5 X6 and X7 have the meanings indicated above.4. The method according to claim 3 , in which the peptide X3 comprises at least 3 contiguous leucines.5. The method according to claim 3 , in which the peptide X3 comprises at least 3 non-contiguous leucines.9. The method according to claim 1 , in which the expression system ...

PEPTIDES FOR THE REGULATION OF NEUROTRANSMITTER SEQUESTRATION AND RELEASE

A method of selecting an agent comprising a neuroprotecting activity is disclosed. The method comprises: 1. A method of selecting an agent comprising a neuroprotecting activity , the method comprising:(a) introducing a plurality of agents into a plurality of cells;(b) analyzing Vesicular Monoamine Transporter 2 (VMAT2) transcription in said cells; and(c) identifying an agent of the plurality of agents capable of up-regulating DJ-1-dependent VMAT2 transcription in said cells, thereby selecting the agent comprising the neuroprotecting activity.2. The method of claim 1 , wherein the agent is a peptide agent.3. The method of claim 1 , wherein the agent is a small molecule.4. The method of claim 2 , wherein said peptide agent comprises a DJ-1 sequence.5. The method of claim 1 , wherein said cell is a neuronal cell.6. The method of claim 5 , wherein said neuronal cell is a neuroblastoma cell.7. The method of claim 1 , wherein said analyzing is effected by determining an interaction between the agent and a promoter region of a Vesicular Monoamine Transporter 2 (VMAT2) polynucleotide.8. The method of claim 1 , wherein said analyzing is effected by a transcription assay.9. The method of claim 8 , wherein said transcription assay is a reporter based assay.10. The method of claim 7 , wherein said promoter region of VMAT2 is endogenous to said cell.11. The method of claim 7 , wherein said promoter region of VMAT2 is exogenous to said cell.12. The method of claim 11 , wherein said promoter region is transcriptionally linked to a detectable polypeptide.13. An agent identified according to the method of .14. The agent of claim 13 , being a peptide agent.15. An isolated peptide or peptide mimetic thereof claim 13 , comprising an amino acid sequence which regulates VMAT2 transcription claim 13 , the peptide being no more than 30 amino acids in length.16. An isolated peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-6 claim 13 , 17-526 and ...

Thioether-, ether-, and alkylamine-linked hydrogen bond surrogate peptidomimetics

Provided herein are peptidomimetics and their salts having a stable, internally constrained protein secondary structure containing a thioether-, ether-, or alkylamine-linked hydrogen bond surrogate; compositions containing at least one of these, and methods of making and using these.

COMPOSITIONS AND METHODS FOR TREATING AIDS OR CANCER BY INHIBITING THE SECRETION OF MICROPARTICLES

Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides. 129-. (canceled)30. A peptide for inhibiting the release of microparticles in a cell , said peptide has a length of 10-100 amino acids and comprises at least two SEQ ID NO: 1 (VGFPV) motifs.31. The peptide of claim 30 , comprising at least one SEQ ID NO: 1 motif at the N-terminal.32. The peptide of claim 30 , comprising at least one SEQ ID NO: 1 motif at the C-terminal.33. The peptide of claim 30 , comprising the amino acid sequence VGFPVAAVGFPV (SEQ ID NO: 2).34. The peptide of claim 30 , comprising the sequence VGFPVAAVGFPVDYKDDDDK (SEQ ID NO: 3).35. A polynucleotide encoding the peptide of .36. The polynucleotide of claim 35 , wherein said peptide comprises the amino acid sequence SEQ ID NO: 2.37. The polynucleotide of claim 35 , wherein said peptide comprises the amino acid sequence of SEQ ID NO: 3.38. An expression vector comprising the polynucleotide of operably linked to a regulatory sequence.39. A pharmaceutical composition claim 35 , comprising:(1) a peptide comprising at least two SEQ ID NO: 1 motifs; and(2) a pharmaceutically acceptable carrier;wherein said SEQ ID NO: 1 containing peptide comprises (a) at least one SEQ ID NO: 1 motif at the N-terminal, or (b) at least one SEQ ID NO: 1 motif at the C-terminal, or (c) at least two SEQ ID NO: 1 motifs.40. The pharmaceutical composition of claim 39 , wherein said peptide comprises at least one SEQ ID NO: 1 motif at the N-terminal.41. The pharmaceutical composition of claim 39 , wherein said peptide comprises at least one SEQ ID NO: 1 motif at the C-terminal.42. The pharmaceutical composition of claim 39 , wherein said peptide comprises the amino acid ...

PEPTIDE FOR IMPROVING BIOSTABILITY OF BIOACTIVE SUBSTANCE, AND BIOACTIVE SUBSTANCE HAVING IMPROVED BIOSTABILITY

The present invention aims at providing a peptide fragment capable of improving biostability of a bioactive substance while maintaining the activity of the bioactive substance, and a bioactive substance to which the peptide fragment is added. The present invention relates to a partial peptide of a GA module having 5 to 25 amino acids, including a partial sequence of a GA module (SEQ ID NO: 1) and the amino acid sequence Ile-Asp-Glu-Ile-Leu (SEQ ID NO: 2), and a bioactive complex in which the partial peptide of the GA module is bound to a bioactive substance. The bioactive substance includes GLP-1, GLP-2, GIP, VIP, somatostatin, amylin, ghrelin, derivatives thereof, and the like. 1. A partial peptide of a GA module , comprising the amino acid sequence: Ile-Asp-Glu-Ile-Leu (SEQ ID NO: 2) and having 5 to 25 amino acids.2. The partial peptide according to claim 1 , wherein the GA module is derived from a streptococcus G148.3. The partial peptide according to claim 1 , which has 5 to 17 amino acids.6. The partial peptide according to claim 1 , which starts with one of the amino acid positions 22 to 38 of the GA module depicted in SEQ ID NO: 1 and ends with one of the amino acid positions 42 to 46 thereof.7. A bioactive complex comprising the partial peptide according to and a bioactive substance bound to the partial peptide.8. The bioactive complex according to claim 7 , wherein the bioactive substance is a gastrointestinal hormone or a derivative thereof claim 7 , or Exendin-4 or a derivative thereof.9. The bioactive complex according to claim 8 , wherein the gastrointestinal hormone is selected from the group consisting of GLP-1 claim 8 , GLP-2 claim 8 , GIP claim 8 , VIP claim 8 , somatostatin claim 8 , amylin and ghrelin.10. The bioactive complex according to claim 7 , further comprising a linker through which the partial peptide and the bioactive substance are bound.12. The bioactive complex according to claim 11 , wherein the GLP-1 or the derivative thereof is ...

Simultaneous synthesis of temperature-tunable peptide and gold nanoparticle hybrid spheres

The present invention relates to a novel synthesis of peptide-gold nanoparticle hybrid spheres comprising a step of forming a hybrid structure by inducing self-assembly of a gold-binding peptide, and forming a gold nanoparticle in the structure at the same time. According to the present invention, size of the structure can be controlled according to temperature, and it can be used for various biomedical and electronic applications using the structure.

Prevention and treatment of cast nephropathy

Provided herein are polypeptides comprising or consisting essentially of a QSYDNTLSGSYVF (SEQ ID NO:1) or LSADSSGSYLYVF (SEQ ID NO:2) amino acid sequence. Also provided herein are methods of treating or preventing cast nephropathy in a subject. The methods comprise identifying a subject with or at risk of developing cast nephropathy and administering to the subject any of the polypeptides disclosed herein.

Peptide having cell membrane penetrating activity

Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be delivered into a cell. Also provided are nucleic acid molecules encoding the transmembrane complex, and methods of delivering the target substance into a cell interior by contacting the transmembrane complex with a cell. Also provided are transfection kits containing the PTD and the target substance.

Polypeptides

A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer. 119-. (canceled)20. A polypeptide comprising a sequence selected from the group consisting of:i) SEQ. ID NOS. 2, 3, 4, 7 or 8;ii) the sequence of an immunogenic fragment of i) comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16; oriii) a sequence having at least 80% sequence identity to i) or ii), wherein the polypeptide is less than 100 amino acids in length and wherein the polypeptide does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58.22. A polypeptide according to wherein the immunogenic fragment has the sequence of any one of SEQ. ID NOS. 17 to 40.23. A polypeptide according to wherein the polypeptide is less than or equal to 80 claim 20 , 50 claim 20 , 30 claim 20 , 20 or 11 amino acids in length.24. A nucleic acid molecule consisting of a nucleotide sequence encoding a polypeptide according to .27. A cocktail of polypeptides according to wherein the at least two different polypeptides comprise a cocktail of polypeptides selected from the group consisting of:i) a cocktail of: a polypeptide comprising the sequence of SEQ. ID NO. 1 or a sequence having at least 80% sequence identity thereto or an immunogenic fragment thereof comprising at least eight amino acids; a polypeptide ...

COMPOSITIONS AND METHODS TO DETECT VARIOUS INFECTIOUS ORGANISMS

The invention relates to compositions and methods for the detection of various infectious organisms, including heartworm (), , and . More particularly, this invention relates to antibodies that bind to a heartworm antigen, the gp36 polypeptide, the p44 polypeptide, the OspA, OspC, OspF, p39, p41 and VlsE polypeptides, and uses thereof. 1Anaplasma phagocytophilumA. phagocytophilumA. phagocytophilum. An p44 polypeptide comprising amino acids 222-236 of SEQ ID NO:1 , wherein said polypeptide comprises at least one mutation , an p44 polypeptide comprising amino acids 222-237 , 222-238 , 222-239 , 222-240 , 222-241 , 222-242 , 222-243 , 222-244 , 222-245 , 222-246 , or 222-247 of SEQ ID NO:1 , or an p44 polypeptide comprising amino acids 222-237 , 222-238 , 222-239 , 222-240 , 222-241 , 222-242 , 222-243 , 222-244 , 222-245 , 222-246 , or 222-247 of SEQ ID NO:1 that comprises at least one mutation.2. A polypeptide comprising a multimer claim 1 , a combination claim 1 , or a chimera of the polypeptides of .3Anaplasma phagocytophilum. An p44 polypeptide that exhibits at least 75% identity to the amino acid sequence of SEQ ID NO:1 claim 1 , or the amino acids 222-237 claim 1 , 222-238 claim 1 , 222-239 claim 1 , 222-240 claim 1 , 222-241 claim 1 , 222-242 claim 1 , 222-243 claim 1 , 222-244 claim 1 , 222-245 claim 1 , 222-246 claim 1 , or 222-247 of SEQ ID NO:1 claim 1 , wherein said polypeptide is not a wild-type P44 protein claim 1 , and wherein said polypeptide binds to an antibody that is specific for a wild-type P44 protein.4Anaplasma phagocytophilumA. phagocytophilum. A polynucleotide which encodes an p44 polypeptide comprising the amino acid sequence of SEQ ID NO:1 claim 1 , or a complimentary strand thereof claim 1 , wherein said polynucleotide is not a wild-type P44 polynucleotide claim 1 , or a polynucleotide which encodes an p44 polypeptide having the amino acid sequence of 222-237 claim 1 , 222-238 claim 1 , 222-239 claim 1 , 222-240 claim 1 , 222-241 claim 1 , ...

MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS AND USES THEREOF

The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample. 1. A monoclonal antibody which binds to a shared epitope of Human Immunodeficiency Virus-1 protein p24 and Human Immunodeficiency Virus-2 protein p26.2. The monoclonal antibody of wherein said antibody is selected from the group consisting of 120A-270 claim 1 , 115B-151 claim 1 , 117-289 claim 1 , 103-350 claim 1 , 115B-303 claim 1 , and 108-394.3. A hybridoma cell line which secretes a monoclonal antibody which binds to a shared epitope Human Immunodeficiency Virus-1 protein p24 and Human Immunodeficiency Virus-2 protein p26.4. The hybridoma cell line of claim 3 , wherein said cell line is selected from the group consisting of A.T.C.C. Deposit No. HB ______ claim 3 , A.T.C.C. Deposit No. HB ______ claim 3 , A.T.C.C. Deposit No. HB ______ claim 3 , A.T.C.C. Deposit No. HB ______ claim 3 , A.T.C.C. Deposit No. HB ______ claim 3 , and A.T.C.C. Deposit No. HB ______.5. A method for detecting the presence of one or more antigens selected from the group consisting of HIV-1 antigen and HIV-2 antigen claim 3 , in a test sample suspected of containing one or more of said antigens claim 3 , comprising the steps of:a) contacting said test sample with at least one monoclonal antibody which binds to a shared epitope of Human Immunodeficiency Virus-1 protein p24 and Human Immunodeficiency Virus-2 protein p26 for a time and under conditions sufficient for the formation of antibody/antigen complexes; andb) detecting said complexes, presence of said complexes indicating presence of at least one antigen selected from the group consisting of HIV ...

EPITOPES OF THE HUMAN PDGF RECEPTOR ABLE TO BIND HUMAN AUTO-ANTIBODIES, ANTIBODIES AND USES THEREOF

The present invention refers to peptides comprised in the extracellular region of human PDGF receptor (hPDGFR) alpha, their use for detecting auto-antibodies anti-hPDGFR alpha and to a method for the diagnosis or the monitoring control for therapy of SSc. The present invention also refers to antibodies or recombinant or synthetic derivatives thereof able to recognize and bind to the above peptide and to their use in the treatment of SSc. 1. A peptide having an amino acid sequence comprised in the extracellular region of human PDGF receptor (hPDGFR) alpha said region consisting of aa. 1-304 of SEQ ID NO. 1 wherein said peptide is an epitope for auto-antibodies anti-hPDGFR alpha.2. A peptide according to comprising aa. 172-186 claim 1 , and/or aa. 141-152 claim 1 , and/or 294-301 of SEQ ID No. 1.3. A peptide according to essentially consisting of aa. 172-186 claim 2 , and/or aa. 141-152 claim 2 , and/or 294-301 of SEQ ID No. 1.4. A peptide according to essentially consisting of aa. 167-190 claim 2 , and/or aa. 138-154 claim 2 , and/or 290-306 of SEQ ID No. 1.5. A peptide according to comprising aa. 36-50 of SEQ ID No. 1.6. A peptide according to essentially consisting of aa. 36-50 of SEQ ID No. 1.7. A peptide according to comprising aa. 42-45 and/or aa. 83-94 and/or aa 199-205 of SEQ ID No. 1.8. A peptide according to essentially consisting of aa. 42-45 and/or aa. 83-94 and/or aa. 199-205 of SEQ ID No. 1.9. Use of at least one peptide according to any of previous claims for detecting auto-antibodies anti-hPDGFR alpha in a biological fluid isolated from a subject.10. Use according to wherein said subject is suspected to be a SSc affected subject.11. A method for the diagnosis or the monitoring control for therapy of SSc characterized in detecting auto-antibodies anti-hPDGFR alpha in a biological fluid isolated from a subject by means of binding to at least one peptide according to to .12. An antibody or a recombinant or synthetic derivative thereof able to recognize ...

LACTADHERIN-DERIVED PEPTIDES AS ANTIVIRAL AGENTS

The present invention relates to monomeric and multimeric peptidic compounds which have antiviral activity, particularly against integrin-using viruses, more particularly against rotavirus. Further, the present invention refers to compositions comprising said peptidic compounds for medical use or for use as food additives. 1. A peptidic compound having a length of up to 50 amino acids and having anti-viral activity , comprising an amino acid sequence represented by the general formula (I){'br': None, 'sub': n', 'm', 'r, 'Z-DGE-W-RGD-Z′\u2003\u2003formula (I)'}or a salt thereof, whereineach of Z, Z′ and W is an amino acid residue, particularly an α-amino carboxylic acid residue,n is a number from 1 to 12, particularly from 1 to 6 and more particularly from 1 to 2, andm is a number from 0 to 12, particularly from 1 to 10 and more particularly from 5 to 8, andr is a number from 0 to 20, particularly from 1 to 12 and more particularly from 1 to 4, and whereinD is an amino acid residue with an aspartic acid side chain, preferably L-aspartic acid,G is an amino acid residue with a glycine side chain,E is an amino acid residue with a glutamic acid side chain, preferably L-glutamic acid, andR is an amino acid residue with an arginine side chain, particularly L-arginine;and wherein the peptidic compound of formula (I) may comprise L- and/or D-amino residues, preferably L-amino acid residues.2. The peptidic compound of claim 1 , wherein the amino acid sequence is represented by the general formula (Ia){'br': None, 'sub': 1', 'n1', '2', 'n2', '3', 'n3', '4', 'n4', '5', 'n5', '1', 'm1', '2', '3', '4', '5, '([Y]-[Y]-DGE-[Y]-[Y]-[Y])-W′-([X]-X-RGD-X-X-X)\u2003\u2003formula (Ia)'}or a salt thereof, wherein{'sub': 1', '2', '3, 'Y, Yand Yare independently amino acid residues with a neutral polar side chain, preferably with a serine (S), asparagine (N), cysteine (C), glutamine (Q), tyrosine (Y) or threonine (T) side chain,'}{'sub': '4', 'Yis an amino acid residue with a positively ...

METHODS OF TREATING AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS) AND NEURODEGENERATIVE DISEASES

An insulin degrading enzyme (IDE) inhibitor for use in the treatment of a disease selected from the group consisting of an autoimmune disease of the central nervous system and a neurodegenerative disease is disclosed. 1. (canceled)2. A method of treating a disease selected from the group consisting of an autoimmune disease of the central nervous system and a neurodegenerative disease , the method comprising administering to a subject in need thereof a therapeutically effective amount of an insulin degrading enzyme (IDE) peptide inhibitor , wherein said IDE peptide inhibitor is selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 2 , SEQ ID NO: 3 , SEQ ID NO: 4 , SEQ ID NO: 5 , SEQ ID NO: 6 , SEQ ID NO: 7 , SEQ ID NO: 8 , SEQ ID NO: 9 , SEQ ID NO: 10 , SEQ ID NO: 11 , SEQ ID NO: 12 , SEQ ID NO:13 , SEQ ID NO: 14 , SEQ ID NO: 15 , SEQ ID NO: 16 , SEQ ID NO: 17 , SEQ ID NO: 18 , SEQ ID NO: 19 , SEQ ID NO: 20 , SEQ ID NO: 21 , SEQ ID NO: 22 , SEQ ID NO: 23 , SEQ ID NO: 24 , SEQ ID NO: 25 , SEQ ID NO: 26 , SEQ ID NO: 27 , SEQ ID NO: 28 , SEQ ID NO: 29 , SEQ ID NO: 30 , SEQ ID NO: 31 , SEQ ID NO: 32 , SEQ ID NO: 33 , SEQ ID NO: 34 , SEQ ID NO: 35 and SEQ ID NO: 36 , thereby treating the disease in the subject.35-. (canceled)6. The method of claim 2 , wherein said IDE peptide inhibitor is as set forth in SEQ ID NO: 6.719-. (canceled)20. The method of claim 2 , wherein said autoimmune disease of the central nervous system is multiple sclerosis.21. The method of claim 2 , wherein said neurodegenerative disease is Alzheimer's disease.22. The method of claim 2 , wherein said autoimmune disease of the central nervous system is selected from the group consisting of multiple sclerosis claim 2 , Guillain-Barre syndrome claim 2 , Lambert-Eaton myasthenic syndrome claim 2 , Myasthenia gravis claim 2 , transverse myelitis claim 2 , progressive multifocal leukoencephalopathy claim 2 , chronic headache and cerebral palsy.23. The method of claim 2 , wherein the subject is a ...

METHODS FOR INHIBITING IMMUNE COMPLEX FORMATION IN A SUBJECT

Polypeptides and other compounds that can bind specifically to the C2-C3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described. 1. A method for inhibiting immune complex formation in a subject , said method comprising administering to said subject a composition comprising a purified polypeptide , said polypeptide comprising the amino acid sequence Cys-Ala-Xaa-His-Leu-Gly-Glu-Leu-Val-Trp-Cys-Thr (SEQ ID NO:8) , wherein Xaa is Trp , Tyr , or Phe.2. The method of claim 1 , wherein said immune complex formation is associated with rheumatoid arthritis.3. The method of claim 2 , further comprising the step of monitoring said subject for clinical or molecular characteristics of rheumatoid arthritis.4. The method of claim 1 , wherein said polypeptide further comprises a terminal stabilizing group.5. The method of claim 4 , wherein said terminal stabilizing group is at the amino terminus of said polypeptide and is a tripeptide having the amino acid sequence Xaa-Pro-Pro claim 4 , wherein Xaa is any amino acid.6. The method of claim 5 , wherein Xaa is Ala.7. The method of claim 4 , wherein said terminal stabilizing group is at the carboxy terminus of said polypeptide and is a tripeptide having the amino acid sequence Pro-Pro-Xaa claim 4 , wherein Xaa is any amino acid.8. The method of claim 7 , wherein Xaa is Ala.9. The method of claim 4 , wherein said terminal stabilizing group is a small stable protein.10. The method of claim 9 , wherein said small stable protein comprises a four-helix bundle topology.11. The method of claim 9 , wherein said small stable protein is Rop.12. The method of claim 1 , wherein said polypeptide further comprises an additional amino acid at the amino terminus of said amino acid sequence.13. The method of claim 12 , wherein said additional amino acid is any amino acid other than Cys.14. The method of claim 12 , wherein said additional amino acid is Asp ...

Eif4e binding peptides

The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.

ANTIMICROBIAL PEPTIDES AND PEPTIDE DERIVATIVES DERIVED FROM ONCOPELTUS FASCIATUS

The present invention relates to a antimicrobial peptide or peptide derivative comprising the following sequence: Sub-X-D-K—P—P—Y-L-P—R—PX—P—P—R—X-T-P—N—N-X-Sub. The invention further relates to multimers comprising said peptides or peptide derivatives. Moreover, the invention provides a peptide or peptide derivative for use in the treatment of a disease. The peptide or peptide derivative may also be used in the screening for novel antimicrobial compounds. 2. A peptide or peptide derivative according to claim 1 , wherein Xi is selected from the group of residues consisting of arginine claim 1 , lysine claim 1 , δ-hydroxylysine claim 1 , homoarginine claim 1 , 2 claim 1 ,4-diaminobutanoic acid claim 1 , β-homoarginine claim 1 , D-arginine claim 1 , arginal claim 1 , 2-amino-3-guanidinopropionate claim 1 , nitroarginine claim 1 , N-methylarginine claim 1 , ε-N-methyllysine claim 1 , allo-hydroxylysine claim 1 , 2 claim 1 ,3-diaminopropionate claim 1 , 2 claim 1 ,2′-diaminopimelic acid claim 1 , ornithine claim 1 , sym-dimethylarginine claim 1 , asym-dimethylarginine claim 1 , 2 claim 1 ,6-Diamino-4-hexynoic acid claim 1 , p-aminobenzoie acid claim 1 , 3-aminotyrosine claim 1 , valine claim 1 , isoleucine claim 1 , leucine methionine claim 1 , alanine claim 1 , phenylalanine claim 1 , N-methyl-leucine claim 1 , tert-butylglycine claim 1 , cyclo-hexylalanine claim 1 , β-alanine claim 1 , 1-aminocylcohexylcarboxylate claim 1 , N-methyl-isoleucine claim 1 , norleucine claim 1 , norvaline and N-methylvaline.3. A peptide or peptide derivative according to claim 1 , wherein Xand Xare independently selected from the group of residues consisting of arginine claim 1 , lysine claim 1 , δ-hydroxylysine claim 1 , homoarginine claim 1 , β-homoarginine claim 1 , D-arginine claim 1 , arginal claim 1 , 2 claim 1 ,4-diaminobutanoic acid claim 1 , 2-amino-3-guanidinopropionic acid claim 1 , nitroarginine claim 1 , nitrosoarginine claim 1 , N-methylarginine claim 1 , ε-N-methyllysine ...

Treatments for Gastrointestinal Disorders

Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (GERD), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein.

Peptides for inhibiting chemokine binding to chemokine receptors

Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.

EEF2K ASSAYS FOR IDENTIFYING COMPOUNDS THAT INHIBIT EEF2K ACTIVITY

Assays for identifying novel compounds for inhibiting eEF2 kinase and consequence peptides employed therein. 14.-. (canceled)5. An isolated peptide comprising a consensus sequence for phosphorylation by TRPM7 kinase comprising a Lys or Arg residue at the +3 position , and a basic residue or Ser or Thr at the +2 position.6. The peptide of claim 5 , comprising the sequence:Ac-RKKYRIVWKSIFRRFL (SEQ. ID. 2)717.-. (canceled)18. The peptide of claim 5 , further comprising Ala claim 5 , Ser claim 5 , Thr claim 5 , Val claim 5 , Ile claim 5 , Leu claim 5 , Gln or Glu at the +1 position.19. The peptide of claim 5 , further comprising Gln or Glu at the −2 position claim 5 , and a charged hydrophilic residue at the −1 position.20. The peptide of claim 18 , further comprising a basic residue at the +4 position. This application claims priority to U.S. Provisional Patent Application No. 61/225,875 filed on Jul. 15, 2009, the contents of which is hereby incorporated by reference in its entirety.This invention was made with government support under Grant No. 5R21RR022859-02 awarded by the National Institutes of Health. The government has certain rights in the invention.The present invention relates to assays for identifying novel compounds for inhibiting eEF2 kinase and consequence peptides employed therein. The present invention is also directed to kits for practicing the scope of the present invention.The enzyme Elongation Factor 2 Kinase (eEF2-K) belongs to a novel family of protein kinases, with prototypical member being Dictyostelium myosin heavy chain kinase A (MHCK A), which display no homology to conventional eukaryotic protein kinases. This protein kinase is highly specific to Elongation Factor 2 (eEF2) and is responsible for eEF2 phosphorylation. eEF2 promotes ribosomal translocation, the reaction that results in the movement of the ribosome along mRNA during translation. eEF2 was identified among the most prominently phosphorylated proteins in crude tissue and cell ...

Peptide Derivatives for Biofunctionalization of Silicon Substrates and Their Applications

The present invention relates to the use of a peptide consisting of 5 to 30 amino acid residues comprising an amino acid sequence selected from LLADTTHHRPWT (SEQ ID NO: 1), SPGLSLVSHMQT (SEQ ID NO: 2), and the sequences presenting at least 80% identity with SEQ ID NO: 1 or SEQ ID NO: 2, for the funcfionalization of silicon substrate. The present invention also relates to the specific peptides as such, and to silicon substrates functionalized by the adsorption on their surface of such specific peptides. Finally, the present invention is also directed to a process for the preparation of such functionalized silicon substrates, and to articles comprising a silicon substrate according to the invention. 1. (canceled)2. (canceled)3. A peptide consisting of 5 to 30 amino acid residues , wherein said peptide comprises an amino acid sequence selected from LLADTTHHRPWT (SEQ ID NO: 1) , SPGLSLVSHMQT (SEQ ID NO: 2) , and the sequences presenting at least 80% identity with SEQ ID NO: 1 or SEQ ID NO: 2.4. A peptide according to claim 3 , wherein said peptide consists of a sequence selected from SEQ ID NO: 1 or SEQ ID NO: 2.5. A silicon substrate which is functionalized by the adsorption on its surface of a peptide as defined according to .6. A silicon substrate according to claim 5 , wherein the silicon substrate is a porous silicon substrate having pores diameters ranging from 15 nm to 200 nm.7. A silicon substrate according to claim 5 , wherein the silicon substrate is a n-doped silicon substrate functionalized by the adsorption on its surface of a peptide comprising SEQ ID NO: 1.8. A silicon substrate according to claim 5 , wherein the silicon substrate is a p-doped silicon substrate functionalized by the adsorption on its surface of a peptide comprising SEQ ID NO: 2.9. A silicon substrate according to claim 5 , wherein the peptide adsorbed on its surface is covalently coupled at one end to a biological ligand.10. A silicon substrate according to claim 9 , wherein the ...

PEPTIDE HAVING CELL MEMBRANE PENETRATING ACTIVITY

Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be delivered into a cell. Also provided are nucleic acid molecules encoding the transmembrane complex, and methods of delivering the target substance into a cell interior by contacting the transmembrane complex with a cell. Also provided are transfection kits containing the PTD and the target substance. 1. An isolated peptide that consists of a sequence of amino acids selected from among SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO:4 , SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO:16 , SEQ ID NO: 22; SEQ ID NO: 26; SEQ ID NO: 27; SEQ ID NO: 31 , SEQ ID NO: 32 , SEQ ID NO: 33 , SEQ ID NO: 34 , SEQ ID NO: 35 , SEQ ID NO: 36 , SEQ ID NO: 37 , SEQ ID NO: 38 , SEQ ID NO: 39 , SEQ ID NO: 40 , SEQ ID NO: 41 , SEQ ID NO: 42 , SEQ ID NO: 43 , SEQ ID NO: 44 , SEQ ID NO: 45 , SEQ ID NO: 46 , SEQ ID NO: 47 , SEQ ID NO: 48; SEQ ID NO: 49 , SEQ ID NO: 50 , SEQ ID NO: 51 , SEQ ID NO: 52 , SEQ ID NO: 53 and SEQ ID NO: 54 , wherein the isolated peptide has cell membrane penetrating activity.2. The peptide of claim 1 , wherein the sequence of amino acids is selected from among one of SEQ ID NO: 2 claim 1 , SEQ ID NO: 3 claim 1 , SEQ ID NO: 4 claim 1 , SEQ ID NO: 12 claim 1 , SEQ ID NO: 13 claim 1 , SEQ ID NO: 14 claim 1 , SEQ ID NO: 15 and SEQ ID NO: 16.3. The peptide of claim 1 , wherein the sequence of amino acids is selected from among one of SEQ ID NO: 22 claim 1 , SEQ ID NO: 26 claim 1 , SEQ ID NO: 27 claim 1 , SEQ ID NO: 31 claim 1 , SEQ ID NO: 32 claim 1 , SEQ ID NO: 33 claim 1 , SEQ ID NO: 34 claim 1 , SEQ ID NO: 35 claim 1 , SEQ ID NO: 36 claim 1 , SEQ ID NO: 37 claim 1 , SEQ ID NO: 38 claim 1 , SEQ ID NO: 39 claim 1 , SEQ ID NO: 40 claim 1 , SEQ ID NO: 41 claim 1 , SEQ ID NO: 42 claim 1 ,SEQ ID NO: 43 claim 1 , SEQ ID NO: 44 claim 1 , SEQ ID NO: 45 claim 1 , SEQ ID NO: ...

Tumor Marker and Methods of Use Thereof

Newly identified proteins as markers for the detection of breast, colon, lung and ovary tumors, or as therapeutic targets for their treatment, affinity ligands capable of selectively interacting with the newly identified markers and methods for tumor diagnosis and therapy using such ligands. 1. A tumor marker for use in the detection of breast , colon , lung and ovary cancer , wherein said tumor marker is:(i) SCARA5 protein in one of its variant isoforms SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:60R SEQ ID NO:7 or a different isoform having sequence identity of at least 80%, preferably at least 90%, more preferably at least 95% to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7; or(ii) a nucleic acid molecule containing a sequence coding for a SCARA5 protein as defined in (i), said encoding sequence being preferably SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO: 11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14.2. A method of screening a sample of breast claim 1 , colon claim 1 , lung or ovary tissue for malignancy claim 1 , said method comprising determining the presence in said sample of a tumor marker according to .3. A method according to claim 2 , wherein said tumor marker is a SCARA5 protein claim 2 , said method being based on immunoradiometric claim 2 , immunoenzymatic or immunohistochemical techniques.4. A method according to claim 2 , wherein said tumor marker is a SCARA5 nucleic acid molecule claim 2 , said method being based on polymerase chain reaction techniques.5. A method in vitro for determining the presence of a breast claim 2 , colon claim 2 , lung or ovary tumor in a subject claim 2 , comprising the steps of:(a) providing a sample of the tissue suspected of containing tumor cells;{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(b) determining the presence of a tumor marker according to in said tissue sample by detecting the expression of the marker protein or the ...

Newly identified colon cancer marker and diagnostic kit using the same

Provided are a newly identified colon cancer marker and a diagnostic kit using the same. More particularly, the present invention relates to an identified colon cancer specific marker, a composition and a kit including agents determining presence of the marker, and a method of diagnosing colon cancer using the same. The diagnostic marker according to the present invention capable of detecting metastasis and prognosis of colon cancer may provide useful information for the treatment and management of colon cancer and be used for the development of colon cancer-specific anticancer agents.

AKT ACTIVITY SPECIFICALLY INHIBITING POLYPEPTIDE

The present invention is to provide a polypeptide specifically inhibiting the activity of Akt (Protein Kinase B), the DNA thereof, the antibody thereof, an inhibitor of Akt activity or an antitumor agent, and the like. The polypeptide comprises polypeptides (SEQ ID NO: 1, 3, 5, 7, and 9 of the sequence listing) that contain an amino acid sequence corresponding to any of the position of amino acid residue 10-24 of human TCL1, amino acid residue 8-22 of human TCL1B, amino acid residue 5-19 of human MTCP1, and amino acid residue 9-24 of mouse or rat TCL1; and the derivatives. Further, the present invention includes DNA encording the polypeptide (SEQ ID NO: 2, 4, 6, 8 or 10 of the sequence listing), and the antibodies specifically binding to the polypeptides. The polypeptide of the present invention can be used for an inhibitor of Akt activity, an antitumor agent, or the like. 1. An isolated DNA encoding a polypeptide that specifically inhibits Akt activity consisting of: the amino acid sequence indicated in SEQ ID NO: 1 or 20 of the sequence listing.2. A recombinant expression vector claim 1 , comprising the DNA according to integrated into a gene expression vector.3. A method for producing a polypeptide that specifically inhibits Akt activity claim 1 , the method comprises{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'introducing the recombinant expression vector according to into a host cell, and'}expressing the recombinant expression vector.4. A method for specifically inhibiting Akt activity claim 1 , the method comprisesintroducing a DNA encoding a polypeptide that specifically inhibits Akt activity consisting of the amino acid sequence indicated in SEQ ID NO: 1 or 20 of the sequence listing, ora recombinant expression vector that comprises the integrated DNA encoding a polypeptide that specifically inhibits Akt activity in the gene expression vector,into living cells to express a polypeptide that specifically inhibits Akt activity.5. A composition for ...

CANCER-TARGETING PEPTIDES AND USES THEREOF IN CANCER TREATMENT AND DIAGNOSIS

Cancer-targeting peptides having a PXLXmotif, in which Xis His or an amino acid residue with a hydrophobic side chain and Xis Pro, Phe, or Trp. Also disclosed herein are conjugates containing the cancer-targeting peptides and uses thereof in cancer treatment and diagnosis. 1. An isolated peptide comprising an amino acid sequence motif PXLX(SEQ ID NO:1) , in which Xis H or an amino acid with hydrophobic side chain , Xis P , F , or W , wherein when Xis L , Xis not P , and when Xis P , Xis not L , and wherein the peptide binds to human glucose-regulated protein 78 (GRP-78).2. The isolated peptide of claim 1 , wherein Xis L claim 1 , H claim 1 , F claim 1 , or W.3. The isolated peptide of claim 1 , wherein the peptide comprises an amino acid sequence of RLLDTNRPXLXY (SEQ ID NO:2).4. The isolated peptide of claim 3 , wherein the peptide comprises an amino acid sequence selected from the group consisting of RLLDTNRPFLPY (P-6) (SEQ ID NO:3) claim 3 , RLLDTNRPHLWY (P-12) (SEQ ID NO:4) claim 3 , and RLLDTNRPFLFY (P-13) (SEQ ID NO:5).5. The isolated peptide of claim 4 , wherein the peptide is selected from the group consisting of RLLDTNRPFLPY (P-6) (SEQ ID NO:3) claim 4 , RLLDTNRPHLWY (P-12) (SEQ ID NO:4) claim 4 , and RLLDTNRPFLFY (P-13) (SEQ ID NO:5).6. A composition comprising (a) the peptide of claim 1 , and (b) an anti-cancer agent.79-. (canceled)10. The composition of claim 6 , wherein the composition further comprises a vehicle carrier.11. The composition of claim 10 , wherein the vehicle carrier is a liposome claim 10 , which encapsulates the anti-cancer agent claim 10 , and wherein the peptide is attached on the surface of the liposome.12. The composition of claim 6 , wherein the peptide is pegylated.13. The composition of claim 6 , wherein the composition comprises an anti-cancer agent claim 6 , which is doxorubicin claim 6 , vinorelbine claim 6 , vincristine claim 6 , paclitaxel or lurtotecan.1419-. (canceled)20. The composition of claim 6 , wherein the composition ...

Comparative ligand mapping from mhc class i positive cells

Compositions that include isolated, functionally active, recombinantly produced class I HLA trimolecular complexes that include epitopes unique to breast cancer cells are disclosed.

PEPTIDES AS ACTIVE AGENTS TO STABILIZE BIOLOGICAL BARRIERS

The present invention relates to compounds, in particular peptides which are capable of stabilizing barrier functions of epithelium and endothelium. The peptides and other compounds of the present invention are useful in the treatment and prevention of diseases or disorders associated with a localized or systemic breakdown of epithelial and endothelial barrier functions. Particular diseases and disorders to be treated and/or prevented with the peptides or other compounds, methods and uses provided herein are burns, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), ventilator induced lung injury (VILI), systemic inflammatory response syndrome (SIRS), acute kidney injury (AKI), sepsis, multiorgan dysfunction syndrome (MODS), or edema. 2. The peptide of which is capable of inhibiting activity of a Rho GTPase.3. Peptide of claim 1 , further comprising Xat the C-terminus of the sequence claim 1 , wherein Xis a moiety selected from the group consisting of NH claim 1 , albumin claim 1 , polyethyleneglycol claim 1 , dextrane claim 1 , ferritine claim 1 , hydroxyethyl-starch and Fc-moiety of an antibody.4. The peptide of claim 1 , wherein Xis R.5. The peptide of claim 1 , wherein Xis L or V.6. The peptide of claim 5 , wherein Xis L.7. The peptide of claim 1 , wherein Xis PPP.8. The peptide of claim 1 , wherein Xis GG.9. The peptide of claim 1 , wherein Xis IS or AS.10. The peptide of claim 9 , wherein Xis IS.11. The peptide of claim 1 , wherein Xis omitted.12. The peptide of claim 1 , wherein Xis R claim 1 , Xis L claim 1 , Xis omitted claim 1 , Xis IS and Xis omitted claim 1 , or wherein Xis R claim 1 , Xis V claim 1 , Xis omitted claim 1 , Xis IS and Xis omitted.14. A polynucleotide encoding the peptide of .15. The peptide of claim 1 , wherein the peptide is comprised in a pharmaceutical formulation.16. A pharmaceutical composition comprising the peptide of and a pharmaceutically acceptable carrier and/or diluent.17. The pharmaceutical composition of for ...

AGENTS FOR TREATING ALZHEIMER'S DISEASE

Agents for treating Alzheimer's disease comprising a peptide according to sequence no. 1 which binds to Aβ oligomers and thus results in the healing or alleviation of Alzheimer's disease. In further embodiments peptides are provided which contain a sequence no. 1, but have preceding sequence sections which allow the peptide to be secreted. For the purpose of gene therapy, corresponding DNA sequences and vectors, in particular according to sequences 3 to 6, are provided. 1. A protein , comprising sequence no. 1.2. A proteincomprising a sequence section according to sequence no. 1 and by comprising a sequence section that causes secretability of the protein.3. The protein according to claim 2 , comprising sequence no. 2.4. Deoxyribonucleic acid claim 2 , coding for a protein according to sequence no. 1.5. The deoxyribonucleic acid according to claim 4 , according to sequence no. 3.6. Deoxyribonucleic acid claim 3 , coding for a peptide according to .7. The deoxyribonucleic acid according to claim 6 , according to sequence no. 4.8. A vector claim 6 , containing a sequence section according to sequence no. 3.9. The vector according to claim 8 , comprising sequence no. 5.10. A vector claim 8 , containing a sequence section according to sequence no. 4.11. The vector according to claim 10 , comprising sequence no. 6.12. A pharmaceutical claim 10 , comprising a protein according to sequence no. 1.13. A pharmaceutical claim 10 , comprising a protein which sequence no. 1 and a sequence section which functionally causes secretability.14. A pharmaceutical claim 10 , comprising a deoxyribonucleic acid according to any one of to .15. A pharmaceutical claim 10 , comprising a vector according to any one of to .16. A method for treating Alzheimer's disease claim 1 , wherein at least one agent according to is introduced into the body. The invention relates to agents for treating Alzheimer's disease,Alzheimer's disease (AD) is the most common form of dementia and today affects more ...

AVß6 PEPTIDE LIGANDS AND THEIR USES

AVβ6 peptide ligands, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AVβ6 mediated diseases. 1. A peptide comprising the sequence motif BRGDLXXL or BRGDLXXI , wherein Bis 6-7 amino acids in length and comprises any amino acids , LXXL or LXXI has an alpha helical structure , Xand Xeach independently represent any amino acid , and the peptide is up to 20 amino acids long.2. A peptide according to claim 1 , wherein the peptide comprises the sequence BRGDLXXLXXX claim 1 , and X claim 1 , Xand Xeach independently represent any amino acid.3. A peptide according to comprising the sequence BRGDLXXLXXXZ claim 2 , wherein each Z is a helix promoting residue and m is any number between 1 and 4.4. A peptide according to claim 1 , wherein Xand Xare helix promoting residues.5. A peptide according to claim 2 , wherein (i) X claim 2 , Xand Xare helix promoting residues; or (ii) X claim 2 , X claim 2 , X claim 2 , Xand Xare helix promoting residues.6. A peptide according to claim 4 , wherein the helix promoting residues are independently selected from the group of Glu claim 4 , Ala claim 4 , Leu claim 4 , Met claim 4 , Gln claim 4 , Lys claim 4 , Arg claim 4 , Val claim 4 , Ile claim 4 , Trp claim 4 , Phe and Asp.7. A peptide according to claim 1 , wherein said alpha helical structure enables the side chains of the L residues of LXXL or the L and I residues of LXXI to align on a single side of the helix.8. A peptide according to claim 1 , wherein said alpha helical structure has 1 to 5 turns.9. A peptide the amino acid sequence of which consists of BRGDLXXLXXXZor BRGDLXXLXXXZ claim 1 , wherein LXXL or LXXI has an alpha helical structure claim 1 , Bis a sequence of n amino acids each of which is any amino acid claim 1 , X claim 1 , X claim 1 , X claim 1 , Xand Xeach independently represent any amino acid claim 1 , each Z is a helix promoting residue independently selected from the group consisting of Glu ...

Polypeptides for the Treatment or Prevention of Cancer and uses Thereof

Disclosed herein are polypeptides or their derivatives and their application. The polypeptides and their derivatives can treat or prevent cancer. The polypeptides of the invention have significant lethality to the cancer cells when used alone. When its clinical commonly used chemotherapy drugs such as cisplatin in combination, it can significantly increase the sensitivity of chemotherapeutic agents on cancer cells, to enhance its lethality of cancer cells, to reduce the dosage. The peptides can kill a variety of cancer cells, but without apparent toxicity enhancing effect on normal cells. The prepared peptides of the present invention can be chemically synthesized, high-purity, low molecular weight, specificity, non-immunogenic, safe and reliable. 1. A peptide having the effect of anti-cancer cells , wherein the amino acid sequence of said peptide is shown as SEQ ID NO.1.2. A peptide having the effect of anti-cancer cells , peptide characterized in that its amino acid sequence of formula: IVHNXXXXGXXWXX , Where , I is isoleucine , V is valine , H is histidine , N is asparagine , G is glycine , W is tryptophan , and Xare variable amino acid residues.3. The peptide of claim 2 , wherein said peptide is: Xis the acidic amino acid or amides of amino acids claim 2 , preferably glutamic acid or glycine claim 2 , Xis an aliphatic amino acid residue claim 2 , preferably is leucine claim 2 , phenylalanine claim 2 , or valine claim 2 , Xis a polar amino acid residues claim 2 , preferably glutamic acid claim 2 , or arginine claim 2 , Xis a polar amino acid residues claim 2 , preferably aspartic acid or arginine claim 2 , Xis an aromatic amino acid claim 2 , acidic amino acid amides claim 2 , amino acid or aliphatic amino acid residue claim 2 , preferably tryptophan claim 2 , phenylalanine claim 2 , tyrosine claim 2 , glutamic acid claim 2 , glutamine claim 2 , or leucine claim 2 , Xis a sulfur-containing amino acid or an aliphatic amino acid residue claim 2 , preferably ...

Peptide antimicrobials

Provided are methods and compositions for in vivo display and screening of peptides for antimicrobial activity. The methods can include expressing a random peptide library in a microbial cell culture and identifying clones in which microbial cell growth or survival is affected by the peptide expressed by that clone. Also provided are peptide antimicrobials identified using these methods and compositions.

TREATMENT OF VIRAL INFECTIONS

The present invention concerns polypeptides derived from a tandem repeat of apoEand their uses as medicaments. The peptides may comprise the tandem repeat, and truncations thereof, for which at least one Leucine (L) is replaced by an amino acid with a side chain comprising at least 4 carbon atoms and at least one Nitrogen atom. Such peptides are useful for preventing or treating viral infections. 122-. (canceled)23. An isolated and purified antiviral polypeptide comprising between 14 and 18 amino acids of the apoEtandem repeat set forth in SEQ ID NO: 2 , wherein said polypeptide comprises one or more amino acid substitutions of an amino acid with a side chain comprising at least 4 carbon atoms and at least one nitrogen atom for leucine (L).24. The polypeptide of claim 23 , wherein the amino acid with a side chain comprising at least 4 carbon atoms and at least one nitrogen atom is arginine (R) or lysine (K).25. The polypeptide of claim 23 , wherein at least two substitutions are made.26. The polypeptide of claim 23 , wherein at least one further leucine amino acid is replaced with Phenylalanine (F) or is deleted.27. The polypeptide of claim 23 , wherein an amino acid is added to the N terminal claim 23 , C terminal and/or between the ninth and tenth amino acids of SEQ ID NO: 2.28. An isolated and purified antiviral polypeptide comprising YRKYRKRYYYRKYRKRYY (SEQ ID NO: 6).29. An isolated and purified antiviral polypeptide comprising LRKLRKLRKLRKLRKLRK (SEQ ID NO: 9).30. A composition claim 23 , comprising the polypeptide of .31. A method of inhibiting viral replication claim 23 , comprising administering to a subject in need of such treatment a therapeutically effective amount of the polypeptide of .32. The method of claim 23 , wherein the polypeptide is the polypeptide of .33. The method of claim 23 , wherein the polypeptide is the polypeptide of .34. The method of claim 23 , wherein the polypeptide is the polypeptide of .35. The method of claim 23 , wherein the ...

Na+/K+-ATPase-Specific Peptide Inhibitors/Activators of Src and Src Family Kinases

A method for regulating Src and its downstream signaling pathway which includes binding between Src and Na+/K+-ATPase is disclosed. The Na+/K+-ATPase/Src complex is a functional receptor for cardiotonic steroids such as ouabain. Also disclosed are Src inhibitors or activators which include either Na+/K+-ATPase or Src that interfere with the interaction between the Na/K-ATPase and Src, act via a different mechanism from ATP analogues, and is pathway (Na+/K+-ATPase) specific. 1. A method for modulating Src activity in a cell in need thereof , the method comprising:administering an effective amount of an active isolated peptide comprised of the amino acid sequence of an isolated Src-modulating peptide (P3) having SEQ ID NO:2, to modulate Src activity in the cell.2. The method of claim 1 , wherein the active isolated peptide comprises a cell-penetrating peptide selected from penatratin (TAT) having SEQ ID NO: 47 and atennapedia (AP) having SEQ ID NO: 48 claim 1 , attached to the isolated Src-modulating peptide (P3).3. The method of claim 1 , wherein the cell is a cancer cell.4. The method of claim 1 , wherein the cell is a prostate cancer cell.5. A method for inhibiting cancer cell growth in a subject in need thereof claim 1 , the method comprising:administering an effective amount of an active isolated peptide comprised of the amino acid sequence of an isolated Src-modulating peptide (P3) having SEQ ID NO:2, effective to inhibit cancer cell growth.6. The method of claim 5 , wherein the active isolated peptide comprises a cell-penetrating peptide selected from penatratin (TAT) having SEQ ID NO: 47 and atennapedia (AP) having SEQ ID NO: 48 claim 5 , attached to the isolated Src-modulating peptide (P3).7. The method of claim 6 , wherein the cancer comprises prostate cancer.8. A method of treating prostate cancer claim 6 , in a subject claim 6 , the method comprising:administering to the subject an amount of at least an active isolated peptide comprised of the amino acid ...

PARSTATIN PEPTIDES

The present invention relates to parstatin peptides, compositions comprising parstatin peptides and their use in the treatment of various disorders, including angiogenesis-related diseases, ocular neovascularisation and related disease states, ischemia-reperfusion injury and myocardial-related disease states, and renal disorders. 1. An isolated peptide comprising a sequence selected from SEQ ID NO:4 (24-41) and SEQ ID NO:1 (1-41) , or a variant , derivative , fragment or homologue thereof.2. (canceled)3. A composition comprising an isolated peptide according to and a pharmaceutically acceptable diluent excipient or carrier.4. An isolated peptide according to claim 1 , or a composition according to claim 1 , for use as a medicament.5. A method of preventing claim 1 , ameliorating or treating a renal disorder in a subject comprising administering to the subject an isolated peptide according to claim 1 , or a composition according to .6. The method according to wherein the renal disorder is a renal injuring event or a renal failure event claim 5 , preferably associated with ischemia-reperfusion injury claim 5 , kidney transplantation claim 5 , the administration of radiocontrast agents claim 5 , the administration of chemotherapy claim 5 , contrast-induced nephropathy claim 5 , sepsis and/or heart failure.7. (canceled)8. Use of an isolated peptide according to claim 5 , or a composition according to claim 5 , in the preparation of a medicament for the treatment of a renal disorder or as a renal protective agent.911-. (canceled)12. A method for preventing claim 5 , ameliorating or treating angiogenesis or an angiogenesis associated disease in a subject comprising administering to the subject an isolated peptide according to claim 5 , or a composition according to .13. The method according to wherein the angiogenesis or angiogenesis associated disease is selected from aberrant angiogenesis claim 12 , diabetic retinopathy claim 12 , retinopathy of prematurity claim 12 , ...

ISOLATION OF MESENCHYMAL STEM CELLS

The present invention relates to peptides or fragments thereof, which peptides bind to mesenchymal stem cells. The present invention also relates to a method for identifying, isolating, specifically selecting and/or enriching mesenchymal stem cells, wherein the peptides, or fragments thereof, are employed for specifically binding to the mesenchymal stem cells. Also, the present invention relates to the use of the peptides of the invention, or fragments thereof, and of the mesenchymal stem cells isolated with the peptides of the invention, or fragments thereof, for treating, injuries and/or degenerated bone, cartilage or tissues. 1. A method for selecting and/or enriching mesenchymal stem cells (MSCs) from a sample , comprising the steps ofcontacting a sample containing mesenchymal stem cells and other cell types with a peptide, or a fragment thereof, wherein the peptide or fragment thereof specifically binds to mesenchymal stem cells, and wherein the peptide is selected from the group consisting of laminin-1, collagen-1, collagen-3, collagen-4, tenascin, thrombospondin-1, osteopontin, fibronectin, vitronectin, and mixtures thereof, thereby allowing binding of the peptide or fragment thereof to mesenchymal stem cells,selecting and/or enriching the mesenchymal stem cells bound to the peptide or fragment thereof from the other cell types not bound to the peptide or fragment thereof.2. The method as claimed in claim 1 , wherein the peptide fragment is:a) a peptide consisting of the amino acid sequence set forth as one of SEQ ID NOs: 8 to 32;b) fragments of the sequences according to a), which have a substantially identical biological activity of the peptide according to a) in an assay relating to the binding of mesenchymal stem cells; orc) a peptide fragment with a sequence that is at least 80% identical one of the sequences stated in a) and b).3. The method as claimed in claim 1 , wherein the sample is from a primary culture or a previously cultured cell population.4. ...

RHAMM BINDING PEPTIDES

The present invention provides for peptides that bind to Receptor for Hyaluronic Acid Mediated Motility (RHAMM) molecules. More specifically, provided are peptides capable of specifically binding RHAMM molecules and capable of binding RHAMM with substantially high affinity. These novel RHAMM-binding peptides provide the basis for new imaging probes that can be used to identify cells expressing RHAMM, and for methods of imaging, prognosis, diagnosis and treatment of conditions associated with RHAMM expression. 1. A RHAMM-binding peptide characterized in that said RHAMM-binding peptide comprises a sequence having a formula EEXEEZ (SEQ ID NO: 18) , wherein X is selected from alanine or glycine , and Z is selected from tyrosine or glutamic acid , or a functional analog thereof.2. A RHAMM-binding peptide characterized in that said RHAMM-binding peptide comprises at least one of the amino acid sequences selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 17 , or a functional analog thereof.3. The RHAMM-binding peptide of claim 2 , characterized in that said RHAMM-binding peptide is selected from SEQ ID NO: 1 claim 2 , SEQ ID NO: 3 claim 2 , SEQ ID NO: 9 claim 2 , SEQ ID NO: 10 claim 2 , SEQ ID NO: 11 claim 2 , SEQ ID NO: 12 and SEQ ID NO: 14 claim 2 , or a functional analog thereof.4. The RHAMM-binding peptide of claim 1 , characterized in that said RHAMM-binding peptide is selected from SEQ ID NO:1 claim 1 , SEQ ID NO:3 claim 1 , SEQ ID NO: 9 claim 1 , and SEQ ID NO:11 claim 1 , or a functional analog thereof.5. The RHAMM-binding peptide of claim 1 , wherein said RHAMM-binding peptide is a tubulin-derived peptide.6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. The RHAMM-binding peptide of characterized in that said RHAMM-binding peptide is conjugated with a detectable label.11. The RHAMM-binding peptide of characterized in that the detectable label is selected from biotin-based labels claim 10 , magnetic labels claim 10 , radioactive labels claim 10 ...

NOCICEPTIN MIMETICS

The present invention relates to nociceptin peptide mimetics that have α-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogues which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described. 2. The peptide according to wherein Ris —NHor —NH(Calkyl).3. The peptide according to wherein Xaais L-Thr.4. The peptide according to wherein Xaais selected from Gly claim 1 , -Ala claim 1 , -Ser claim 1 , -Lys claim 1 , -Arg claim 1 , -Pro claim 1 , -Glu claim 1 , -Ile claim 1 , -Met claim 1 , -Val claim 1 , -Ala claim 1 , -Ser claim 1 , -Lys claim 1 , -Arg claim 1 , -Pro claim 1 , -Glu claim 1 , -Ile claim 1 , -Leu claim 1 , -Met or -Val.5. The peptide according to wherein Xaais selected from Gly claim 4 , -Lys claim 4 , -Ala claim 4 , -Ala claim 4 , -Arg and -Glu.6. The peptide according to wherein Xaais Gly or -Lys.7. The peptide according to wherein Xaais selected from -Arg claim 1 , -Lys claim 1 , -Orn claim 1 , -Ala claim 1 , -Leu claim 1 , -Met claim 1 , -Glu claim 1 , -Gln claim 1 , -Cys claim 1 , -Val claim 1 , -Ile claim 1 , -Phe claim 1 , -Tyr claim 1 , -Trp claim 1 , -Thr claim 1 , Gly claim 1 , -Ser and -Asp.8. The peptide according to wherein Xaais -Arg or -Lys.9. The peptide according to wherein Xaais selected from -Lys claim 1 , -Orn claim 1 , -Arg claim 1 , -His claim 1 , -2 claim 1 ,3-diaminopropionic acid and -2 claim 1 ,4-diaminobutanoic acid.10. The peptide according to wherein Xaais -Lys.11. The peptide according to wherein Xaais selected from -Ser claim 1 , -Ser claim 1 , -Thr claim 1 , -Cys claim 1 , -Asn claim 1 , -Gln claim 1 , -Tyr claim 1 , -Ala claim 1 , -Val claim 1 , -Leu claim 1 , -Ile claim 1 , -Met claim 1 , -Phe claim 1 , -Trp claim 1 , -Pro claim 1 , -Arg and Gly. ...

Novel Peptides for Wound Healing

The present invention relates to new peptides, pharmaceutical composition and cosmetic composition comprising them and their use for wound healing. 115.-. (canceled)16. A peptide of less than 50 amino acids comprising one of SEQ ID NO: 1 , SEQ ID NO: 2 , SEQ ID NO: 3 , SEQ ID NO: 4 , SEQ ID NO: 5 or SEQ ID NO: 6 , or comprising a fragment of at least 8 amino acids of any of these.17. The peptide of claim 16 , further defined as consisting of 8 to 30 amino acids.18. The peptide of claim 16 , wherein said peptide is chemically modified by an acetylation and/or an amidation.19. A composition comprising at least one peptide or fragment of .20. The composition of claim 19 , wherein the composition is a pharmaceutical composition comprising a pharmaceutically acceptable excipient.21. The pharmaceutical composition of claim 20 , further comprising an haemostatic substance claim 20 , a growth factor claim 20 , an anti-infective substance claim 20 , an analgesic substance claim 20 , an anti-inflammatory substance and/or a combination thereof.22. The composition of claim 19 , further defined as a cosmetic composition.23. The composition of claim 19 , further defined as being in a form suitable for topical claim 19 , injectable claim 19 , oral and/or parenteral administration.24. The composition of claim 19 , further defined as being in a form suitable for topical administration further defined as a lotion claim 19 , salve claim 19 , gel claim 19 , cream claim 19 , balsam claim 19 , tincture claim 19 , cataplasm claim 19 , elixir claim 19 , paste claim 19 , spray claim 19 , collyrium claim 19 , drops claim 19 , suspension claim 19 , dispersion claim 19 , hydrogel claim 19 , ointment claim 19 , emulsion or powder.25. A medical device comprising at least one peptide or fragment of .26. The medical device of claim 25 , further defined as a bandage claim 25 , gauze claim 25 , wound or sore dressing claim 25 , dermal patch claim 25 , or adhesive tape.27. A method for healing a ...

LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE

The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu. 1. A conjugate comprising a ligand that binds to Her2/neu and a second domain , wherein said second domain consists of a 12 to 100 amino acid sequence that includes a peptide selected from KFAKFAKKFAKFAKK , KFAKFAKKFAKFAKKF , KFAKFAKKFAKFAKKFA , KFAKFAKKFAKFAKKFAK , KFAKFAKKFAKFAKKFAKF and KFAKFAKKFAKFAKKFAKFA , or a 12 to 100 amino acid sequence that includes a peptide selected from KFAKFAKKFAKFAKK , KFAKFAKKFAKFAKKF , KFAKFAKKFAKFAKKFA , KFAKFAKKFAKFAKKFAK , KFAKFAKKFAKFAKKFAKF and KFAKFAKKFAKFAKKFAKFA having one or more of the K residues substituted with any of an F or L residue , one or more of the F residues substituted with any of a K , A or L residue , or one or more of the A residues substituted with any of a K , F or L residue.2. A conjugate comprising a ligand that binds to Her2/neu and a second domain , wherein said second domain consists of an amino acid sequence selected from KFAKFAKKFAKFAKK , KFAKFAKKFAKFAKKF , KFAKFAKKFAKFAKKFA , KFAKFAKKFAKFAKKFAK , KFAKFAKKFAKFAKKFAKF and KFAKFAKKFAKFAKKFAKFA; or an amino acid sequence selected from KFAKFAKKFAKFAKK , KFAKFAKKFAKFAKKF , KFAKFAKKFAKFAKKFA , KFAKFAKKFAKFAKKFAK , KFAKFAKKFAKFAKKFAKF and KFAKFAKKFAKFAKKFAKFA having one or more of the K residues substituted with any of an F or L residue , one or more of the F residues substituted with any of a K , A or L residue , or one or more of the A residues substituted with any of a K , F or L residue.3. The conjugate of or , wherein said ligand that binds to Her2/neu comprises a peptide , polypeptide , protein , nucleic acid or carbohydrate.4. The conjugate of or , wherein said ligand that binds to Her2/neu has a linear or cyclic structure.5. The conjugate of or , wherein said ligand ...

ANTICANCER FUSION PROTEIN

The fusion protein, especially recombinant, comprising domain (a) which is a functional fragment of soluble hTRAIL protein sequence beginning with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% homology thereto; and domain (b) which is a sequence of pro-apoptotic effector peptide, wherein the sequence of domain (b) is attached at C-terminus and/or N-terminus of domain (a). The fusion protein has anticancer activity. The nucleotide sequence coding the fusion protein, expression vector and host cell for the preparation of the fusion protein, and the use of the fusion protein for treating cancer diseases. 1. A fusion protein comprising:domain (a) which is the functional fragment of soluble hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% homology thereto; anddomain (b) which is the sequence of a pro-apoptotic effector peptide, which effects its pro-apoptotic action via intrinsic apoptosis pathway, wherein the sequence of domain (b) is attached at the C-terminus and/or the N-terminus of domain (a).2. The fusion protein according to wherein domain (a) is the fragment of soluble hTRAIL protein sequence claim 1 , which fragment begins with an amino acid from the range hTRAIL95 to hTRAIL121 claim 1 , inclusive claim 1 , and ends with the amino acid hTRAIL281.3. The fusion protein according to claim 2 , wherein domain (a) is selected from the group consisting of hTRAIL114-281 (SEQ. No. 27) claim 2 , hTRAIL119-281 (SEQ. No. 28) claim 2 , hTRAIL121-281 (SEQ. No. 29) claim 2 , hTRAIL116-281 and hTRAIL120-281.4. The fusion protein according to claim 1 , wherein domain (a) is the sequence hTRAIL95-281.5. The fusion protein according to claim 1 , wherein domain (b) is selected from the group consisting of:the fragment of BH3 domain of Bax protein of SEQ. No. 30;the fragment of Bid protein of SEQ. No. 31;ribonuclease A of SEQ. No. 32;cytochrome C of SEQ. ...